US20050279349A1 - Method and device for delivering aerosolized medicaments - Google Patents

Method and device for delivering aerosolized medicaments Download PDF

Info

Publication number
US20050279349A1
US20050279349A1 US10/693,318 US69331803A US2005279349A1 US 20050279349 A1 US20050279349 A1 US 20050279349A1 US 69331803 A US69331803 A US 69331803A US 2005279349 A1 US2005279349 A1 US 2005279349A1
Authority
US
United States
Prior art keywords
chamber
medicament
gas
aerosol
apparatus according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/693,318
Inventor
John Patton
Robert Platz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma AG
Original Assignee
Patton John S
Platz Robert M
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US72491591A priority Critical
Priority to US07/910,048 priority patent/US5458135A/en
Priority to US31370794A priority
Priority to US08/576,885 priority patent/US5775320A/en
Priority to US08/979,024 priority patent/US6138668A/en
Priority to US09/561,690 priority patent/US6681767B1/en
Application filed by Patton John S, Platz Robert M filed Critical Patton John S
Priority to US10/693,318 priority patent/US20050279349A1/en
Publication of US20050279349A1 publication Critical patent/US20050279349A1/en
Assigned to NOVARTIS PHARMA AG reassignment NOVARTIS PHARMA AG ASSIGNMENT OF PATENT RIGHTS Assignors: NEKTAR THERAPEUTICS
Application status is Abandoned legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0057Pumps therefor
    • A61M16/0063Compressors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/001Particle size control
    • A61M11/002Particle size control by flow deviation causing inertial separation of transported particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0001Details of inhalators; Constructional features thereof
    • A61M15/0013Details of inhalators; Constructional features thereof with inhalation check valves
    • A61M15/0015Details of inhalators; Constructional features thereof with inhalation check valves located upstream of the dispenser, i.e. not traversed by the product
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0065Inhalators with dosage or measuring devices
    • A61M15/0066Inhalators with dosage or measuring devices with means for varying the dose size
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0065Inhalators with dosage or measuring devices
    • A61M15/0068Indicating or counting the number of dispensed doses or of remaining doses
    • A61M15/008Electronic counters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0086Inhalation chambers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10Preparation of respiratory gases or vapours
    • A61M16/105Filters
    • A61M16/106Filters in a path
    • A61M16/107Filters in a path in the inspiratory path
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/06Solids
    • A61M2202/064Powder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/07General characteristics of the apparatus having air pumping means
    • A61M2205/071General characteristics of the apparatus having air pumping means hand operated
    • A61M2205/073Syringe, piston type
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2206/00Characteristics of a physical parameter; associated device therefor
    • A61M2206/10Flow characteristics
    • A61M2206/16Rotating swirling helical flow, e.g. by tangential inflows

Abstract

A device for accurately delivering aerosolized doses of a medicament disperses a measured amount of drug in a measured volume of carrier gas and transfers the resulting aerosol to a chamber prior to inhalation by a patient. The chamber is filled efficiently with the aerosol, and inhalation by the patient draws the aerosol dose into the lungs. This is followed by the inhalation of atmospheric air that will push the initial dose well into the lung interiors. The apparatus optimally includes a dose regulator, a counter, a clock, a dose memory and a signal to indicate when a dose is ready for inhalation. Optimal chamber designs are disclosed.

Description

  • The present invention is a continuation of U.S. application Ser. No. 08/979,024, filed Nov. 26, 1997; U.S. application Ser. No. 08/576,885, filed Dec. 22, 1995; Ser. No. 08/313,707, filed Sep. 27, 1994; Ser. No. 07/910,048, filed Jul. 8, 1992; and a continuation-in-part of application Ser. No. 07/724,915, filed on Jul. 2, 1991, the full disclosures of which are incorporated herein by reference.
  • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • This invention relates to a structure and method of administering precisely measured doses of a therapeutic by inhalation.
  • An accurate mechanism for delivering precise doses of aerosol drugs into the interior of human lungs has been an objective of many workers in the art. One of the most popular aerosol delivery devices is the propellent-driven metered dose inhaler (MDI), which releases a metered dose of medicine upon each actuation. Although these devices may be useful for many medicines, only a small variable percentage of the medicine is delivered to the lungs. The high linear speed with which the dosage leaves the device, coupled with incomplete evaporation of the propellants, causes much of the medicine to impact and stick to the back of the throat. This impacting and sticking creates a local concentration of drugs much of which is eventually swallowed. In the trade, this impact area is called a “hot spot” and can cause local immuno-suppression and the development of fungal infections with bronchosteriods. With broncodilators, for instance, the swallowed dose can contribute to unwanted systemic side effects such as tremor and tachycardia.
  • MDI's also require a degree of coordination between activation and inhalation. Many patients are incapable of this task, especially infants, small children and the elderly. In an effort to overcome some of the above limitations of MDI's, others have interposed “spacers” between the conventional MDI and the patient. The primary function of these spacers is to provide extra volume to allow time for increased propellent droplet evaporation prior to inhalation and to reduce the velocity and impact of the medicine at the back of the throat. Although spacers do compensate for some of the inadequacies in the conventional MDI, it has been found that much of the medicine that may have ordinarily been deposit d on the throat remains in the spacer and the total dose deposited in the lungs is small. It has been found that only approximately 8% of the medicine reaches the interior of the lung with conventional MDI's. Approximately 13% of the medicine reaches the lung when it is equipped with a spacer.
  • Other workers in the art have attempted to provide a metered dose of a medicant by using dry powder inhalers (DPI). Such devices normally rely on a burst of inspired air that is drawn through the unit. However, these units are disadvantaged in that the force of inspiration varies considerably from person to person. Some patients are unable to generate sufficient flow to activate the unit. DPI's have many of the disadvantages of MDI's in that a large percentage of the medicant is deposited in the throat because of incomplete particle dispersion and the impact at the rear of the throat. Although pocket size MDI's and DPI's are very convenient they have disadvantages some of which are cited above.
  • Other workers in the art have refined aqueous nebulization delivery systems. Although such systems require a continuous gas compressor, making them less portable than the MDI's and the DPI's, many nebulizers provide a low velocity aerosol which can be slowly and deeply inhaled into the lungs. Precision of dosage delivery, however, remains a serious problem and it is difficult to determine how much medicament the patient has received. Most nebulizers operate continuously during inhalation and exhalation. Dosage is dependent on the number and duration of each breath. In addition to breath frequency and duration, the flow rate, i.e., the strength of the breath that is taken from a nebulizer can effect the particle size of the dose inhaled. The patient's inhalation acts as a vacuum pump that reduces the pressure in the nebulizer. A strong breath can draw larger unwanted particles of medicant out of the nebulizer. A weak breath, on the other hand, will draw insufficient medicant from the nebulizer.
  • Electro-mechanical ventilators and devices have also been used in recent years to deliver inhalable materials to a patient. These devices permit mixing of a nebulized medicant into breathing circuit air only during pre-set periods of a breathing cycle. An example of this type of machine is the system taught by Edgar et al., in their U.S. Pat. No. 4,677,975, issued in July of 1987 where a nebulizer is connected to a chamber which in turn is connected to a mouthpiece, an exhaust valve, and an inlet valve. A breath detector and timer are used to deliver nebulized materials to the patient during a portion of the breathing cycle. However, in Edgar and others of this type, the patient's intake strength can effect the nebulizer operation with many of the consequences heretofore mentioned. Moreover, the amount of nebulized material delivered in each breath can vary significantly, contributing to inaccurate total dosages. In a modification of Edgar et al. (Elliott, et al. (1987) Australian Paediatr. J. 23:293-297), filling of the chamber with aerosol is timed to occur during the exhalation phase of the breathing cycle so that the patient is not inhaling through the device during nebulization. This design, however, requires that the patient maintain a constantly rhythmic breathing pattern into and out of the device, which is inconvenient and can contaminate the device with oval microbes. Moreover, no provision is made on the devices to efficiently capture the aerosol in the chamber so that as many as 80 breaths or more must be taken to obtain a dose of medication.
  • The delivery of therapeutic proteins and polypeptides by inhalation presents additional problems. Many protein drugs are produced recombinantly and can thus be very expensive. It is therefore important that loss of a protein drug within the delivery device be reduced or preferably eliminated. That is, substantially all drug initially charged within the device should be aerosolized and delivered to the patient without loss within the device or released externally of the device. The protein drugs should further be delivered to the patient under conditions which permit their maximum utilization. In particular, protein drugs should be completely dispersed into small particles in the preferred 1 μm to 5 μm size range which is preferentially delivered to the alveolar region of the lungs. The amount of protein drug delivered to the patient in each breath must also be precisely measured so that the total dosage of drug can be accurately controlled. Finally, it will be desirable to permit the delivery of highly concentrated aerosols of the protein drug so that the number of breaths required for a given dosage can be reduced, thus increasing accuracy and reducing the total time required for administration.
  • 2. Description of the Background Art
  • U.S. Pat. Nos. 4,926,852 and 4,790,305, describe a type of “spacer” for use with a metered dose inhaler. The spacer defines a large cylindrical volume which receives an axially directed burst of drug from a propellant-driven drug supply. U.S. Pat. No. 5,027,806, is an improvement over the '852 and '305 patents, having a conical holding chamber which receives an axial burst of drug. U.S. Pat. No. 4,624,251, describes a nebulizer connected to a mixing chamber to permit a continuous recycling of gas through the nebulizer. U.S. Pat. No. 4,677,975, is described above. European patent application 347,779 describes an expandable spacer for a metered dose inhaler having a one-way valve on the mouthpiece. WO 90/07351 describes a dry powder oral inhaler having a pressurized gas source (a piston pump) which draws a measured amount of powder into a venturi arrangement.
  • SUMMARY OF TEE INVENTION
  • The present invention provides methods and apparatus for producing an aerosolized dose of a medicament for subsequent inhalation by a patient. The method comprises first dispersing a preselected amount of the medicament in a predetermined volume of gas, usually air. The dispersion may be formed from a liquid, for example by injecting an air stream through a liquid reservoir of the drug, or from a dry powder, for example by drawing the powder into a flowing air stream from a reservoir using a venturi or other dispersion nozzle. The present invention relies on flowing substantially the entire aerosolized dose into a chamber which is initially filled with air and open through a mouthpiece to the ambient. The aerosolized dose of medicament flows into the chamber under conditions which result in efficient displacement of the air with the aerosolized material. By “efficient displacement,” it is meant that at least 40% by weight of the aerosolized material entering the chamber will remain aerosolized and suspended within the chamber, thus being available for subsequent inhalation through the mouthpiece. It is further meant that very little or none of the aerosolized material will escape from the chamber prior to inhalation by the patient. Efficient displacement of air and filling of the chamber can be achieved by proper design of the chamber, as discussed below.
  • After the aerosolized medicament has been transferred to the chamber, the patient will inhale the entire dose in a single breath. Usually, the total volume of aerosolized medicament and air within the chamber will be substantially less than an average patient's inspiratory capacity, typically being about 100 ml to 750 ml. In this way, the patient can first inhale the entire amount of drug present in the dose and continue in the same breath to take in air from the ambient which passes through the chamber and which helps drive the medicament further down into the alveolar region of the lungs. Conveniently, the steps of aerosolizing the medicament, filling the chamber, and inhalation of the chamber contents may be repeated as many times as necessary to provide a desired total dosage of the medicament for the patient.
  • Apparatus according to the present invention comprise both a dispersion device for aerosolizing the medicament, either from a liquid or dry powder formulation of the medicament, and a chamber having an air inlet and patient mouthpiece for receiving the aerosolized medicament from the dispersion device. The chamber is designed and connected to the dispersion device in such a way that the aerosolized medicament will flow into the chamber and efficiently displace the internal air volume, as described above. The volume of the chamber will be at least as large as the maximum expected volume of aerosolized medicament to be transferred from the dispersion device. Usually, the chamber volume will be greater than the aerosol volume in order to reduce losses through the mouthpiece, with exemplary chamber volumes being in the range from 100 ml to 750 ml, as described above. The volume of aerosolized medicament will usually be in the range from 50 ml to 750 ml when the dispersion device is a liquid nebulizer and from 10 ml to 200 ml when the dispersion device is a dry powder disperser, as described in more detail below. In order to enhance efficient filling, the chamber will preferably define an internal flow path so that the entering aerosolized medicament will follow the path and displace air within the chamber without substantial loss of the medicament through the mouthpiece. Alternatively, the chamber may include a baffle which acts to entrap a high velocity aerosol, particularly those associated with dry powder dispersions.
  • In a preferred aspect, the chamber is generally cylindrical and is connected to the dispersion device by a tangentially disposed aerosol inlet port located at one end of the cylinder The mouthpiece is then located at the opposite end of the cylinder, and aerosolized medicament flowing into the chamber will follow a generally vortical flow path defined by the internal wall of the chamber. By also providing an ambient air inlet at the same end of the cylindrical chamber, the patient can first inhale the medicament and thereafter breath in substantial amounts of ambient air, thus sweeping the interior of the chamber to efficiently remove substantially all aerosolized medicament present and help drive the medicament further into the patient's lungs.
  • In further preferred aspects, the ambient air inlet of the chamber will be protected, typically through a one-way valve structure which permits air inflow but blocks aerosol outflow, so that aerosol will not be lost as it enters the chamber. The chamber may also comprise vortical baffles, typically in the form of an axially aligned tube or conical cylinder within the interior of the chamber, to restrict dispersion of the aerosol within the chamber and improve delivery efficiency.
  • In an alternate preferred aspect, the chamber is generally cylindrical with an axially oriented aerosol inlet port located at one end. The mouthpiece is located at the other end of the cylinder, and an internal baffle is located between the aerosol inlet and the mouthpiece to prevent direct passage of the aeros 1 to the mouthpiece (which could result in loss of medicament well before the chamber has been efficiently filled). The internal baffle is preferably hemispherical in shape with a concave surface oriented toward the aerosol inlet. Such a construction has been found particularly useful in initially containing dry powder dispersions which are often introduced using a high velocity (frequently sonic) gas stream. The chamber further includes a tangential ambient air inlet port disposed in the chamber wall between the aerosol inlet and the internal baffle. By inhaling through the mouthpiece, the patient is able to establish a vortical flow of ambient air which will sweep the contained aerosol past the baffle and through the mouthpiece.
  • In yet another aspect of the present invention, the apparatus for producing aerosolized doses of a medicament comprises the dispersing device, means for delivering pressurized gas to the dispersing device, the aerosol chamber, and a controller capable of selectively controlling the amount of pressurized air delivered to the dispersing device in order to produce the desired single doses of medicament and deliver said doses to the chamber. The controller may include means for timing the actuation of a compressor or means for controlling the amount of gas released from a pressurized cylinder, as well as a mechanism for counting and displaying the number of doses delivered from the chamber during a particular period of use. Still further, the controller may include a microprocessor and a keypad for inputting information to the microprocessor.
  • In exemplary devices, the controller may comprise a timer connected to selectively actuate a valve, such as a solenoid valve, on a gas cylinder. Alternatively, the timer may turn on and off an air compressor to regulate the amount of air delivered to the dispersing device. In portable and hand-held apparatus, the controller may simply be a release button or mechanism that actuates a spring or air driven piston to deliver a specific amount of gas. The controller could also be a metered valve which could release a fixed amount of liquid propellant to the dispersing device (in a manner similar to a metered dose inhaler).
  • The method and the apparatus of the present invention are particularly effective for delivering high value drugs, such as polypeptides and proteins, to a patient with minimal loss of the drug in the device. Moreover, the method and device provide for a very accurate measurement and delivery of the doses, while employing relatively simple and reliable equipment. Further advantages of the present invention include the ability to vary the total dosage delivered, either by controlling the number of breaths taken or by controlling the amount of medicament in each breath. Still further, the method and device of the present invention permit the delivery of relatively concentrated doses of the medicament in order to reduce the amount of time and number of breaths required for the delivery of a total dosage of the medicament, particularly when using dry powder medicament formulations.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a schematic-diagrammatic view of the invention;
  • FIG. 2 is a diagrammatic cross-sectional view of a holding chamber;
  • FIG. 3 is a diagrammatic view of the holding chamber;
  • FIG. 4 is a cross-section along the line 4-4 of FIG. 3;
  • FIG. 5 is a cross-section along the line 5-5 of FIG. 3;
  • FIG. 6A-6D are diagrammatic views disclosing the stages of operation; and
  • FIG. 7 illustrates a venturi nozzle which may be used for dispersing dry powder medicament formulations when used in systems constructed in accordance with the principles of the present invention;
  • FIGS. 8-11 illustrate various exemplary chambers which may be used in the aerosol delivery systems of the present invention.
  • DESCRIPTION OF THE SPECIFIC EMBODIMENTS
  • The method and device of the present invention are useful for delivering a wide variety of medicaments, drugs, biologically active substances, and the like, to a patient's lung, particularly for systemic delivery of the medicament or the like. The present invention is particularly useful for delivering high value medicaments and drugs, such as proteins and polypeptides, where efficient delivery and minimum loss are of great concern.
  • The apparatus of the present invention will usually comprise the following basic components: a means for producing a metered volume of gas, a mixing chamber for generating an aerosol bolus from either a liquid or a powder, a reservoir that contains the medicament, and a holding chamber that efficiently captures the aerosol bolus to maintain the aerosolized particles in suspension and allow a patient to inhale the aerosol by a slow, deep inspiration, thereby effectively distributing the aerosolized medicament to the distal region of the lungs.
  • A gas source will usually deliver a preselected volume of gas at greater than about 15 psig in order to produce a sonic velocity jet in an aerosol producing region (although sonic velocity is not always necessary). The pressurized gas is required to efficiently atomize the liquid or break apart the powder producing an aerosol having particles that are predominantly 1 to 5 μm in diameter. In addition, the volume of the gas bolus must be less than a fraction of a patient's inspiratory volume, preferably between 100 to 750 ml. Suitable gas sources include:
      • 1) an air compressor with a timer to control the operating period of the compressor (where the timer comprises at least a portion of the controller discussed hereinafter);
      • 2) a compressed gas cylinder with a solenoid valve controlled by a timer;
      • 3) a liquid propellant with a metering valve and an evaporation chamber;
      • 4) a spring piston pump; and
      • 5) a pneumatic pump.
  • The means for producing the aerosol will usually consist of a constricted orifice that produces a high velocity gas flow to atomize a liquid or break apart powder agglomerates. The present invention is designed to be used with a conventional jet nebulizer that operate with airflow rates in the range from 3 to 13 L/min at about 15 psig, with the flow rate depending largely on the nozzle geometry of the nebulizer. The present invention further provides a means of controlling the volume of air delivered to the nebulizer in order to produce an aerosol bolus having a specific volume that can be contained in the aerosol holding chamber. By controlling the gas source to deliver a specific volume of gas, the system can employ a variety of nebulizers available from commercial vendors, such as Marquest, Hudson, Baxter, and Puritan Bennett.
  • The present invention can also operate with a powder jet disperser as a means of generating an aerosol. A pressurized gas jet produces a highly turbulent gas flow that serves to break apart powder agglomerates producing an aerosol having single particles of the preformed powder. An example of a suitable powder/gas mixing chamber is a simple nozzle with a venturi ejector, as shown in FIG. 7. An advantage of this type of powder mixer is that the gas flow through the nozzle is only a fraction of the entrained airflow through the venturi. This reduces the air capacity so that the required volume of gas for dispersing the powder could be delivered from a small “pocket-sized” gas source.
  • In addition, the powder dispersing apparatus must produce a pressure pulse having a long enough duration (typically 0.01 to 1 second) to adequately fluidize the powder and efficiently dispense the powder from the reservoir. A small diameter nozzle, less than 0.020 inch is acceptable and less than 0.015 inch is preferable, in order to achieve an acceptable duration of the pressure pulse at peak pressures exceeding 15 psig with a volume of gas that is small enough to be contained in a small holding chamber.
  • Referring now to the drawings wherein like numerals indicate like parts, the numeral 10 generally indicates an exemplary apparatus constructed in accordance with the principles of this invention. The apparatus is powered by an electrical source 12 that provides energy for a controller, typically in the form of a microprocessor 18. The present invention, however, does not require the use of an electrical or digital controller, so long as some means is provided for supplying preselected gas volumes for aerosol bolus.
  • The microprocessor 18 is a general purpose microcontroller unit (MCU) such as that sold by Motorola under their Model Number 68HC05. This unit has on-chip peripheral capabilities and the on-board memory system 30. The on-chip peripheral capability of the Motorola unit includes multiple input ports, one of which receives the input data from the keypad 13 via line 16. The microprocessor 18 has a plurality of output ports and its functioning will be more fully understood as the components of the invention are described.
  • Keypad 13 has six input keys that are important to performance, namely; 13 a, 13 b, 13 c, 13 d, 13 e and 13 f. The volume or amount of each aerosolized dose is selected by controlling the length of time a compressor 22 is turned on by pressing the “puff size” button 13 a. The keypad 12 is programmed so that a first press of button 13 a will display a choice of puff sizes on an LCD 32. Additional pressings of the button will select the desired size. A “puff counter actuator” button 13 b is pressed which will cause the LCD 32 display “00”. A second press of 13 b energizes the air compressor 22 via output line 38 for a 13 a. This produces the first aerosolized dose or bolus of a medicament for inhalation. The LCD display 32 will change from 00 to 01 and the LCD will increase by one upon each additional activation of the compressor. The patient will continue activating puffs with button 13 b until the prescribed number of puffs have been taken. As these puff events are occurring, the time and number are stored in memory 30.
  • T view a record of previous uses of the device, a dosage recall button 13 c is pressed which causes LCD 32 to display prior dates, times, puff sizes and number of puff formation events. Successive pressings of the button 13 c will enable scrolling of the patient's dosage history. Reversal of scroll direction is accomplished by pressing button 13 d and then continuing to scroll with 13 c. The button 13 e is a clock/calendar button. Pressing the button 13 e causes the LCD 32 to display the current date and time. After the device is used and a series of puffs have been taken, the system will automatically default five minutes after the last puff to display the actual time and date on the LCD display. Thus, the device is a clock/calendar when not in actual use and during the use and date or time can be viewed by pressing 13 e.
  • Air from compressor 22 is communicated to a mixer 40. The mixer 40 may be a nebulizer, a dry powder dispenser or other type of nebulizer known to the prior art. When unit 40 is a dry powder dispenser, the compressed air from compressor 22 may optionally be first subjected to coalescing filter 41 and a desiccant filter 41 a. When unit 40 is a nebulizer, a particle filter 21 may optionally be placed at the intake 23 of the compressor to filter out articles before the air is compressed. In either case, the medicament or drug will preferably be in the form of a small particulate, usually having an aerodynamic size in the range from 1 μm to 5 μm. It is known that particles in this size range are most efficiently delivered to the alveolar regions of the lungs.
  • An exemplary dry powder venturi nozzle 200 is illustrated in FIG. 7. The venturi nozzle 200 includes a side port 202 which receives an initial charge of powder medicament M, typically a lyophilized protein or polypeptide. The powder is drawn into dispersion chamber 204 at the point where nozzle orifice 206 introduces a high velocity gas stream in the direction of arrow 208. The high velocity gas stream will result from pressurized gas or air in plenum 210, which may be provided by a separate air compressor 22 (FIG. 1) or an air or gas cylinder (not illustrated). The low pressure caused by the air or gas stream will draw the powder continuously into the dispersion chamber 204 where agglomerates of the powder are broken into smaller sizes within the preferred 1 μm to 5 μm range by the turbulent shear effect in the chamber.
  • In any event, unit 40 is of a type that will nebulize or mix a defined amount of medicant with the preselected amount of compressed air received from compressor 22. This defined amount, referred to as a dosage or bolus, flows into a chamber 42 via the conduit 39. The chamber 42 is transparent, typically having a glass, transparent plastic, or similar wall 44.
  • A critical aspect of the present invention is the ability to transfer the aerosolized medicament from the mixer 40 into the chamber 42 without substantial loss of medicament through the mouthpiece or within the chamber. Such losses will be minimized so that at least about 40% by weight of the medicament delivered to the chamber will remain aerosolized and suspended within the chamber after the entire volume has been transferred. Preferably, at least about 55% will remain suspended, more preferable at least about 70%. Such low losses are desirable since the total amount of drug which may be introduced into the chamber for each transfer is maximized, and thus the amount which may be inhaled in each breath by a patient is increased. Additionally, even small losses of high valued drugs, such as proteins and polypeptides, can become significant over time. Still further, the ability to deliver a concentrated aerosol dispersion of drug into the chamber will increase the concentration of drug delivered to the patient with each breath. Such high concentration dosages are preferable since they can reduce the total number of breaths necessary to deliver a prescribed amount of drug, thus increasing the total amount of time required for the treatment.
  • Loss of aerosolized medicament can be reduced by minimizing mixing between the aerosolized medicament and the displaced air as the chamber is being filled. Minimum mixing between the aerosol transferred from the mixing chamber 40 and the displaced air within chamber 42 can be enhanced by properly designing the chamber 42 as well as the inlet flow geometry of the aerosol into the chamber. Particularly preferred geometries are illustrated in FIGS. 2-5 and 8-11, as described in more detail hereinbelow.
  • A light 50 and/or an audible signal 52 will alert the user that a puff is ready to be withdrawn from chamber 42 when the compressor 22 shuts down. At this point in time, the aerosolized bolus of medicine is quite visible. From the holding chamber 42 the medicament is inhaled by the patient via a conduit 45 through a mouthpiece 46 or in the case of small children or infants , a face mask 48. A one-way check valve 47 is disposed across conduit 45 to prevent exhalation into chamber 42. The signals 50 and 52 are set to begin immediately after operation of the compressor 22 ceases. The cessation of the compressor sound will also alert the patient that bolus formation is complete. This sequence is repeated for each bolus and the microprocessor 18 will count and record each instance of compressor activation so that the prescribed number of aerosolized boluses have been administered. The number of boluses, their hour and date and their size (time f compressor use), are recorded, stored and recallable at a future time f r display on LCD 32 by pressing dosage history button 13 c.
  • One embodiment of the aerosol holding chamber 42 is best seen in cross-section in FIG. 2. The chamber 42 is comprised basically of a top 54, the previously mentioned transparent sidewall 44 and a bottom 58. The chamber 42 is equipped with an aerosol intake stub fitting 60 at the lower portion thereof. The chamber top is equipped with an inhalation stub 62. Also at the bottom 58 is an atmospheric intake stub 64. The stubs are formed to accept conventional connector fittings 70, 72 and 74 respectively. The fittings connect the conduits 45, 96 and 80 to the stub-fillings 60, 62 and 64. The fittings permit the ready interchange of chambers having different volumetric capacities.
  • Disposed in a conduit 39, between unit 40 and chamber 42, is a valve 80 that is opened before use of the device and closed between uses. The valve 80 serves as a vapor lock to prevent evaporation of fluid from unit 40 when the nebulizer is not in use. Valve 80 can be controlled by hand like a stop-clock, or it may be electronically controlled by the MCU 18 so that upon pressing the puff counter/actuator button 13 b, valve 80 opens and then closes by default if the machine is not used for a set period. Disposed across inhale line 45 is a one-way check valve 47. A one-way check valve 94 is also disposed across the air intake conduit 96.
  • Particularly preferred chamber geometries are illustrated in FIGS. 8-11. Chamber 100 in FIG. 8 comprises a cylindrical body 102 with a tangential aerosol inlet port 104. The tangential aerosol inlet port 104 will be connected to a suitable aerosol dispersing device, usually either a nebulizer or a dry powder device (as described above), preferably a nebulizer, and the aerosol will enter and assume a vortical flow pattern, as indicated by arrows 106. The entry of the aerosol will displace air initially present in the chamber 100 through mouthpiece 108. Usually, but not necessarily, the chamber 100 will be oriented vertically with the mouthpiece at the top. After the entire aerosol bolus has entered the chamber 100 (typically only partially filling the chamber leaving a “buffer” of air near the mouthpiece 108), the patient will inhale through the mouthpiece 108, drawing in ambient air through ambient air inlet 110, thus sweeping the chamber of the aerosolized medicament. Ambient air inlet 110 will usually have a one-way valve, such as a flap or diaphragm valve (not illustrated) in order to prevent loss of aerosol as the aerosol is introduced through port 104.
  • Chamber 120 in FIG. 9 is similar to chamber 100, except that an inlet tube 122 extends into the chamber interior, forming a vortical baffle. Apertures 124 are disposed about the inlet tube 122 to permit entry of air as the patient inhales through mouthpiece 126. Ambient air inlet 128 is similar to inlet 104 in FIG. 8.
  • A horizontally disposed chamber 140 is illustrated in FIG. 10. Chamber 140 includes both a tangential aerosol inlet 142 and tangential mouthpiece 144. Thus, aerosolized medicament will enter through the inlet 142 and move horizontally across the chamber interior toward the mouthpiece 144. An advantage of this design is that the aerosol particles will tend to drop below the level of the mouthpiece 144 as they cross the chamber. Thus, loss of the medicament through the mouthpiece 144 will be minimized. Ambient air inlet 146 is provided to permit air infusion as the patient inhales through the mouthpiece 144.
  • A preferred chamber 150 for use with dry powder dispersion devices, such as venturi nozzle 200 in FIG. 7, is illustrated in FIG. 1A. The chamber 150 will generally be maintained with its axis oriented vertically, with an aerosol inlet 152 at its lower end and a mouthpiece 154 at its upper end. The chamber 150 further includes an internal baffle 156 which is suspended from a rod 158 attached to the upper end of the chamber. The baffle 156 is preferably hemispherical, with its open or concave end oriented downwardly toward aerosol inlet 152. The purpose of the baffle 156 is to contain the initial plume of aerosol created by the high velocity air or gas stream. The hemispherical design is preferred since it will redirect the initial flow of aerosol back downward, creating a recirculation as indicated by the arrows in FIG. 11B. Other geometries for the baffle, including flat plates, perforated plates, cylinders, cones, and the like, might also find use, with the primary requirement being that the baffle design be able to provide an initial containment zone within the chamber.
  • After an aerosolized dose or bolus of medicament has been introduced to the chamber 150, the patient will inhale through the mouthpiece 154, drawing ambient air in through ambient air inlet 158. The inlet 158 includes a one-way flap or diaphragm valve 160 which permits the inflow of air but prevents the initial loss of medicament as the aerosolized dose enters through the inlet 152. The ambient air inlet 158 is disposed tangentially on the chamber 150, and entry of ambient air through the inlet cause a vortical (as illustrated in FIG. 11C) which will cause the suspended medicament particles to move radically outward (due to the induced cyclone effect) and be carried upward by the airflow through the annular region 162 between the periphery of the baffle 156 and the interior wall of the chamber 150.
  • Surprisingly, the design of chamber 150 has been found to be able to receive a volume of aerosolized medicament greater than the chamber volume without substantial loss of medicament through the mouthpiece. It is believe that the baffle 156 can act as a “concentrator,” which contains the medicament particles in the region below the baffle while permitting air flow through the annular region 162. Such concentration is achieved while still maintaining the aerosolized particles in suspension and with the ability to subsequently transfer the medicament particles to the mouthpiece by introducing a vortical flow of ambient air through inlet 158, as described above.
  • In operation, the patient or medical attendant will ready the device by operating the puff size button 13 a. Button 13 b is pressed a second time to energize compressor 22 and a pre-selected amount of air under a constant pressure is delivered to unit 40 for mixing or nebulizing to form the first puff. The medicament begins filling the chamber 42 from the bottom (FIG. 6A) through valve 80 and stub fitting 60 and a cloudy, observable “puff” is formed as seen in FIG. 6B. During this time interval, valve 94 is closed.
  • After the vessel or chamber 42 is filled, the signals 50 and 52 are activated for several seconds by the timer function of the microprocessor 18. The duration of both signals will be preset in the control program 24. As a breath is taken, valves 47 and 94 will open to permit the puff to enter the lungs and to permit additional atmospheric air to enter the chamber from the bottom through conduit 96.
  • The volumetric size of chamber 42 is only a fraction of the capacity of the patients' lungs usually being from 200 ml to 1000 ml, typically being about 500 ml. Inhalation by the patient will thus initially draw the entire dose of medicament into the lungs. The volume of aerosol transferred to the chamber will typically be about 10 ml to 750 ml, and the air that enters through valve 94 can thus act as an air piston to drive the smaller volume of aerosol deep into the user's lungs. The bottom to top filling and vertical flow pattern result in a minimum of dispersion and dilution of the aerosol. Moreover, the sweeping of chamber 50 with air after each inhalation helps assure substantially complete delivery of the drug to the patient.
  • The atmospheric or pure air and the medicament bolus, each moves from the chamber 42 through the one-way check valve 47 into the patient's mouth via the conduit 45. A mask 48 with a one-way exhalation port is used for patients that require same. A one-way valve 47 may be used to prevent the patient from accidentally exhaling into the chamber 42.
  • FIG. 6A-6D show illustrations of the sequence of bolus generation and withdrawal from the aerosol holding chamber 42.
  • The following examples are offered by way of illustration, not by way of limitation.
  • Experimental Equipment
  • Air supply—a nitrogen cylinder with a regulator, a needle valve, a pressure gauge, and a solenoid valve that is operated with a timer with a resolution of 0.01 second.
  • Jet Nebulizer—Rapid-Flo™, (Allersearch, Vt. Victoria, Australia)
  • Powder Disperser—A venturi (as illustrated in FIG. 7) having a 0.013 inch diameter jet nozzle.
  • Aerosol Holding Chambers—Fabricated from plastic with internal volumes of 750 ml. Design 1—3-inch cylindrical chamber with spherical top and bottom and one 90°-port at the base, one 45°-port at the top and one tangential port on the side (as illustrated in FIG. 8). Design 2—3-inch cylindrical chamber with spherical top and bottom and a 1 inch cylindrical spacer located axially along the center of the chamber. Three ports—one 90°-port at the base, one 45°-port at the top and one tangential port on the side (as illustrated in FIG. 9). Design 3—3-inch cylindrical chamber with spherical top and bottom; a 2½ inch hemispherical baffle held in the center of the chamber with a rod. The baffle was located approximately 2inches above the base of the chamber. Three ports—aerosol intake: 90°-port at the base, mouthpiece: 45°-port at the top and makeup air intake: tangential port on the side (as illustrated in FIG. 11). Design 4—3-inch cylindrical chamber with spherical top and bottom; a 2½ inch hemispherical baffle located 2¾ inches above the base on a c ne (as illustrated in FIG. 11).
  • Methods
  • The four aerosol chamber designs were tested using either the jet nebulizer or the powder dispenser. Design 1 was tested using either the 90°-port at the base for the aerosol intake or the tangential port as the aerosol intake.
  • The total airflow through the apparatus, the aerosol generator and the holding chamber, was measured with a rotameter connected to the mouthpiece of the holding chamber. The flow was set to the desired rate with the needle valve. The pressure was maintained above 15 psig to ensure sonic velocity in the nozzle of the aerosol generator.
  • Once the airflow was set, the sample was loaded into the aerosol generator. The operating period was set on the timer. A toggle switch on the timer opened the solenoid valve sending air through the aerosol generator and producing the aerosol. We observed the distribution of the aerosol in the holding chamber and could observe when the aerosol began to flow out of the chamber. The maximum length of time that the aerosol generator could be operated and still capture all of the aerosol in the holding chamber was determined by adjusting the operating period on the timer and repeating the steps listed above. The aerosol dose volume was calculated from the flow rate and the time the solenoid was open. A vacuum line was connected to the holding chamber following an actuation to clear the chamber of the aerosol before actuating again.
  • A 0.9% saline solution was used in testing the different holding chamber configurations with a Rapid-Flow nebulizer. The nebulizer was operated at flow rate of 19 L/min which resulted in 24 psig across the jet of the nebulizer.
  • The powder disperser was tested at a pressure of 30 psig which resulted in a flow rate of 10.4 L/min through the apparatus. Approximately 5 mg of a test powder, prepared by spray drying a solution of mannitol and bovine serum albumin, was loaded into the venturi intake and the solenoid valve was actuated. We checked for powder remaining in the venturi intake to determine whether there was an adequate air supply to disperse the powder. The particle size distribution measured from the chamber using an Aerosizer (API, Hadley, Mass.) particle size analyzer showed that the aerosol contained particles between 1 and 4 μm in diameter.
  • Results
  • Results comparing the different chamber designs for containing the aerosol are reported in Table 1. The maximum volume of the aerosol contained by the chamber was calculated from the maximum operating time and the total airflow. The proportion of the aerosol volume to the volume of the chamber given in the % Chamber Volume column is a way of comparing the effectiveness of the different chamber designs for containing the aerosol. The air volume needed to disperse 5 mg of powder could be efficiently captured in all of the chamber configurations tested. The designs that induced a vertical airflow pattern in the chamber retained a larger volume of aerosol.
    TABLE 2
    Aerosol Capture Efficiency for several
    Holding Chamber Designs
    Nebulizer Powder Disperser
    % of Increase % of Increase
    Cham- Aerosol Chamber over Aerosol Chamber over
    ber Volume Volume base Volume Volume base
    De- 348 mL 45.8% 69. mL 9.24%
    sign 1
    bottom
    fill
    De- 665 mL 86.7% 1.94 95.3 mL 12.7% 1.38
    sign 1
    tangen-
    tial
    fill
    De- 728 mL 97.1% 2.12 104 mL 13.9% 2.50
    sign 2
    center
    baffle
    De- 950 mL  127% 2.77 164 mL 21.9% 2.37
    sign 3
    hemi-
    sphere
    baffle
    De- 855 mL  114% 2.49 161 mL 21.5% 2.33
    sign 4
  • Conclusions
  • An aerosol holding chamber can be designed that efficiently captures a measured volume of aeros 1. A chamber designed to induce vortical airflow pattern in the chamber by a tangential aerosol intake or using baffles distributes the aerosol more evenly in the chamber without loss from the mouthpiece. For use with a nebulizer, a vortical airflow produces a higher concentration of medicament in the chamber so that an effective dose could be taken with fewer puffs. The results with the powder disperser show that the vortical flow and properly designed baffles are effective in containing a powder aerosol produced by a turbulent jet.
  • It should be understood that the preferred embodiments of the present invention have been disclosed by way of example and that other modifications may occur to those skilled in the art without departing from the scope and spirit of the appended claims.

Claims (19)

1. (canceled)
2. Au apparatus for producing aerosolized medicament, the apparatus comprising:
a reservoir containing a powder medicament to be aerosolized, the powder medicament comprising a protein or polypeptide; and
a chamber comprising an inlet and a mouthpiece, wherein gas may flow into the chamber through the inlet and may flow out of the chamber through the mouthpiece and wherein the flow of gas aerosolizes the powder medicament,
wherein at least 40 percent by weight of the powder medicament is suspended by the gas in the chamber for delivery rough the mouthpiece.
3. An apparatus according to claim 2 wherein the chamber volume is from 100 ml to 750 ml.
4. An apparatus according to claim 2 further comprising a source of compressed gas, wherein the compressed gas may be released if the source of compressed gas to cause the flow of gas to aerosolize the medicament.
5. An apparatus according to claim 2 wherein the chamber is adapted contain the aerosolized medicament for subsequent delivery to a patient during a patient's inhalation.
6. An apparatus according to claim 2 wherein the chamber is cylindrical.
7. An apparatus according to claim 2 when the aerosolizes medicament comprises small particles of medicament, the particles being sized to be deliverable to the alveolar regions of the lungs of a patient.
8. An apparatus according to claim 7 wherein the particles are predominantly 1 to 5 micrometers in diameter.
9. An apparatus according to claim 2 wherein at least 55 percent by weight of the powder medicament is suspended by the gas in the chamber for delivery through die mouthpiece.
10. An apparatus according to claim 2 wherein at least 70 percent by weight of the powder medicament is suspended by the gas in the chamber for delivery through the mouthpiece.
11. An apparatus for producing aerosolized medicament, the apparatus comprising:
a reservoir containing a powder medicament to be aerosolized, the powder medicament comprising a protein or polypeptide; and
a chamber comprising an inlet and a mouthpiece, wherein gas may flow into the chamber through the inlet and may flow out of the chamber through the mouthpiece and wherein the flow of gas aerosolizes the powder medicament,
wherein the volume of the aerosolized medicament is from 9.24 percent to 21.5 percent of the volume of the chamber.
12. An apparatus according to claim 11 wherein the chamber volume is from 100 ml to 750 ml.
13. An apparatus according to claim 11 further comprising a source of compressed gas, wherein the compressed gas may be released from the source of compressed gas to cause the flow of gas to aerosolize the medicament.
14. An apparatus according to claim 11 wherein the chamber is adapted contain the aerosolized medicament for subsequent delivery to a patient during a patient's inhalation.
15. An apparatus according to claim 11 wherein the chamber is cylindrical.
16. An apparatus according to claim 11 wherein the aerosolizes medicament comprises small particles of medicament, the particles being sized to be deliverable to the alveolar regions of the lungs of a patient.
17. An apparatus according to claim 16 wherein the particles are predominately 1 to 5 micrometers in diameter.
18. An apparatus according to claim 11 wherein at least 40 percent by weight of the powder medicament is suspended by the gas in the chamber for delivery through the mouthpiece.
19. An apparatus according to claim 11 where at least 70 percent by weight of the powder medicament is suspended by the gas in the chamber for delivery trough the mouthpiece.
US10/693,318 1991-07-02 2003-10-24 Method and device for delivering aerosolized medicaments Abandoned US20050279349A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US72491591A true 1991-07-02 1991-07-02
US07/910,048 US5458135A (en) 1991-07-02 1992-07-08 Method and device for delivering aerosolized medicaments
US31370794A true 1994-09-27 1994-09-27
US08/576,885 US5775320A (en) 1991-07-02 1995-12-22 Method and device for delivering aerosolized medicaments
US08/979,024 US6138668A (en) 1991-07-02 1997-11-26 Method and device for delivering aerosolized medicaments
US09/561,690 US6681767B1 (en) 1991-07-02 2000-05-01 Method and device for delivering aerosolized medicaments
US10/693,318 US20050279349A1 (en) 1991-07-02 2003-10-24 Method and device for delivering aerosolized medicaments

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/693,318 US20050279349A1 (en) 1991-07-02 2003-10-24 Method and device for delivering aerosolized medicaments

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/561,690 Continuation US6681767B1 (en) 1991-07-02 2000-05-01 Method and device for delivering aerosolized medicaments

Publications (1)

Publication Number Publication Date
US20050279349A1 true US20050279349A1 (en) 2005-12-22

Family

ID=24912427

Family Applications (4)

Application Number Title Priority Date Filing Date
US07/910,048 Expired - Lifetime US5458135A (en) 1991-07-02 1992-07-08 Method and device for delivering aerosolized medicaments
US08/576,885 Expired - Lifetime US5775320A (en) 1991-07-02 1995-12-22 Method and device for delivering aerosolized medicaments
US08/979,024 Expired - Fee Related US6138668A (en) 1991-07-02 1997-11-26 Method and device for delivering aerosolized medicaments
US10/693,318 Abandoned US20050279349A1 (en) 1991-07-02 2003-10-24 Method and device for delivering aerosolized medicaments

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US07/910,048 Expired - Lifetime US5458135A (en) 1991-07-02 1992-07-08 Method and device for delivering aerosolized medicaments
US08/576,885 Expired - Lifetime US5775320A (en) 1991-07-02 1995-12-22 Method and device for delivering aerosolized medicaments
US08/979,024 Expired - Fee Related US6138668A (en) 1991-07-02 1997-11-26 Method and device for delivering aerosolized medicaments

Country Status (12)

Country Link
US (4) US5458135A (en)
EP (3) EP0592540B1 (en)
JP (1) JP3230056B2 (en)
KR (1) KR100246082B1 (en)
AT (2) AT359842T (en)
AU (1) AU662919B2 (en)
CA (2) CA2112674C (en)
DE (4) DE69230613D1 (en)
DK (1) DK0592540T3 (en)
ES (2) ES2141108T3 (en)
GR (1) GR3032973T3 (en)
WO (1) WO1993000951A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060249144A1 (en) * 2005-05-05 2006-11-09 Pulmatrix Inc. Ultrasonic Aerosol Generator
US20080066741A1 (en) * 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
US20120172788A1 (en) * 2008-04-09 2012-07-05 Bio Bath Corporation Mobile apparatus for the dispersion and transdermal delivery of pharmaceutical, medical or purified carbon dioxide gas
WO2013076654A1 (en) * 2011-11-21 2013-05-30 Levin, Orna Breathing biofeedback device
JP2014236973A (en) * 2013-06-06 2014-12-18 ヘレウス メディカル ゲーエムベーハー Medical spraying device with pressure relief valve, and method for producing spray cone
WO2015012758A1 (en) * 2013-07-22 2015-01-29 Inhalation Sciences Sweden Ab Apparatus and method for generating an aerosol
EP2900133A4 (en) * 2012-09-25 2016-05-25 Inhalation Sciences Sweden Ab Exposure system for aerosol and model material interaction
US9642798B2 (en) 2010-09-29 2017-05-09 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
US9737518B2 (en) 2013-04-01 2017-08-22 Pulmatrix Operating Company, Inc. Tiotropium dry powders

Families Citing this family (408)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8909891D0 (en) * 1989-04-28 1989-06-14 Riker Laboratories Inc Device
US5993805A (en) * 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
US6205999B1 (en) 1995-04-05 2001-03-27 Aerogen, Inc. Methods and apparatus for storing chemical compounds in a portable inhaler
US6427682B1 (en) 1995-04-05 2002-08-06 Aerogen, Inc. Methods and apparatus for aerosolizing a substance
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6681767B1 (en) 1991-07-02 2004-01-27 Nektar Therapeutics Method and device for delivering aerosolized medicaments
DK0592540T3 (en) * 1991-07-02 2000-06-26 Inhale Inc Method and device for delivering aerosolized medications
US6019968A (en) * 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
CA2145418A1 (en) 1992-09-29 1994-04-14 John S. Patton Pulmonary delivery of active fragments of parathyroid hormone
US5888477A (en) * 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US20010003739A1 (en) * 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
CZ295827B6 (en) 1994-03-07 2005-11-16 Nektar Therapeutics Method for aerosolizing a dose of insulin, insulin composition and use thereof
US20030113273A1 (en) * 1996-06-17 2003-06-19 Patton John S. Methods and compositions for pulmonary delivery of insulin
CA2190502A1 (en) * 1994-05-18 1995-11-23 Robert M. Platz Methods and compositions for the dry powder formulation of interferons
EP0682955B1 (en) * 1994-05-19 2001-09-05 PARI GmbH Spezialisten für effektive Inhalation Device for drying and buffering aerosols
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
BR9508964A (en) 1994-09-21 1998-06-02 Inhale Therapeutic Syst Process and apparatus aerosolization feed tube assembly and the receptacle for containing a powdered medicament
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5522385A (en) * 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
MY131733A (en) 1994-12-22 2007-08-30 Astra Ab Aerosol drug formulations
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5513630A (en) * 1995-03-08 1996-05-07 Century; Theodore J. Powder dispenser
US5603314A (en) * 1995-03-22 1997-02-18 Bono; Michael Aerosol filtration device and inhalation apparatus containing same
US6165463A (en) * 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
WO1997002857A1 (en) * 1995-07-10 1997-01-30 A & D Company, Limited Atomizer
US5758637A (en) 1995-08-31 1998-06-02 Aerogen, Inc. Liquid dispensing apparatus and methods
GB2310607A (en) * 1996-02-29 1997-09-03 Norton Healthcare Ltd Spacer device for inhalers
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US6792940B2 (en) * 1996-05-13 2004-09-21 Universidad De Sevilla Device and method for creating aerosols for drug delivery
US6299145B1 (en) 1996-05-13 2001-10-09 Universidad De Sevilla Device and method for fluid aeration via gas forced through a liquid within an orifice of a pressure chamber
US6187214B1 (en) 1996-05-13 2001-02-13 Universidad De Seville Method and device for production of components for microfabrication
US6595202B2 (en) 1996-05-13 2003-07-22 Universidad De Sevilla Device and method for creating aerosols for drug delivery
EP1039971B1 (en) 1997-12-17 2003-05-21 Universidad de Sevilla Device and method for creating aerosols for drug delivery
US6386463B1 (en) 1996-05-13 2002-05-14 Universidad De Sevilla Fuel injection nozzle and method of use
ES2140998B1 (en) 1996-05-13 2000-10-16 Univ Sevilla Liquid atomization process.
US6450189B1 (en) 1998-11-13 2002-09-17 Universidad De Sevilla Method and device for production of components for microfabrication
US6189803B1 (en) 1996-05-13 2001-02-20 University Of Seville Fuel injection nozzle and method of use
US6116516A (en) * 1996-05-13 2000-09-12 Universidad De Sevilla Stabilized capillary microjet and devices and methods for producing same
US6196525B1 (en) 1996-05-13 2001-03-06 Universidad De Sevilla Device and method for fluid aeration via gas forced through a liquid within an orifice of a pressure chamber
US6405936B1 (en) 1996-05-13 2002-06-18 Universidad De Sevilla Stabilized capillary microjet and devices and methods for producing same
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
FR2751553B1 (en) * 1996-07-23 1999-06-11 Pedrali Franck Method for the improvement of the distribution of a bronchodilator spray products and devices implementing it
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
GB2318737B (en) * 1996-10-30 2000-06-14 Bespak Plc Improved inhalers
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US6349719B2 (en) 1997-02-24 2002-02-26 Aradigm Corporation Formulation and devices for monitoring the efficacy of the delivery of aerosols
US6192882B1 (en) 1997-02-24 2001-02-27 Aradigm Corporation Formulation and devices for monitoring the efficacy of the delivery of aerosols
TW533865U (en) * 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
CA2212430A1 (en) * 1997-08-07 1999-02-07 George Volgyesi Inhalation device
US6394085B1 (en) * 1997-09-25 2002-05-28 Norton Healthcare Ltd. Inhaler spacer
US6073629A (en) * 1997-09-25 2000-06-13 Norton Healthcare Ltd. Inhaler spacer
GB9720283D0 (en) * 1997-09-25 1997-11-26 Norton Healthcare Ltd Inhaler spacer
US6345617B1 (en) 1997-09-26 2002-02-12 1263152 Ontario Inc. Aerosol medication delivery apparatus and system
US6293279B1 (en) 1997-09-26 2001-09-25 Trudell Medical International Aerosol medication delivery apparatus and system
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
PE56799A1 (en) 1997-10-10 1999-06-10 Inhale Therapeutic Syst Method and apparatus for conveying powder
NZ504021A (en) * 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
US6009869A (en) * 1997-12-29 2000-01-04 Allegiance Corporation Supersonic nozzle nebulizer
TW581681B (en) 1998-02-20 2004-04-01 Nektar Therapeutics Liquid crystal forms of cyclosporin
AP1342A (en) * 1998-03-16 2004-12-15 Nektar Therapeutics Aerosolized active agent delivery
US6113078A (en) 1998-03-18 2000-09-05 Lytesyde, Llc Fluid processing method
JP2002507577A (en) * 1998-03-25 2002-03-12 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ Trimer antigenic o- binding complex glycopeptide, their preparation and use thereof
US6257233B1 (en) * 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
US6152130A (en) * 1998-06-12 2000-11-28 Microdose Technologies, Inc. Inhalation device with acoustic control
JP2002524107A (en) 1998-06-12 2002-08-06 マイクロドース・テクノロジーズ・インコーポレーテッド Weighing of pharmaceuticals and drugs and packaging more transport
US6142146A (en) * 1998-06-12 2000-11-07 Microdose Technologies, Inc. Inhalation device
US6062213A (en) * 1998-06-16 2000-05-16 Fuisz Technologies Ltd. Single unit dose inhalation therapy device
DE19851279B4 (en) * 1998-06-17 2006-05-24 GSF - Forschungszentrum für Umwelt und Gesundheit GmbH Inhalation unit for supplying medicines to the lungs
US6260549B1 (en) * 1998-06-18 2001-07-17 Clavius Devices, Inc. Breath-activated metered-dose inhaler
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US6593133B1 (en) 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
CN1896231B (en) 1998-08-06 2012-09-05 山景药品公司 Method for separating tetramer uric acid oxydiazing enzyme
AT399541T (en) 1998-08-18 2008-07-15 Univ California Epidermal growth factor receptor antagonists for the treatment greatly increased mucus secretion in the lungs
IL126200D0 (en) * 1998-09-14 1999-05-09 Aerotron Medical Instrumentati Nebulizer
PE12812000A1 (en) * 1998-10-09 2000-11-08 Inhale Therapeutic Syst Aerosolized active agent delivery modulated flow resistance
US6234167B1 (en) 1998-10-14 2001-05-22 Chrysalis Technologies, Incorporated Aerosol generator and methods of making and using an aerosol generator
GB2344533B (en) * 1998-12-11 2000-10-18 Bespak Plc Improvements in or relating to dispensing apparatus
EP2191718A1 (en) 1998-12-22 2010-06-02 The University of North Carolina at Chapel Hill Compounds and uses for the treatment of airway diseases and for the delivery of airway drugs
US6223744B1 (en) 1999-03-16 2001-05-01 Multi-Vet Ltd. Wearable aerosol delivery apparatus
PT1165050E (en) * 1999-04-05 2006-06-30 Mannkind Corp Processes for forming fine powder
CA2369262A1 (en) 1999-04-13 2000-10-19 Sudha Nagarajan Pulmonary administration of dry powder formulations for treating infertility
DE19917347A1 (en) * 1999-04-16 2000-11-09 Gsf Forschungszentrum Umwelt Method and apparatus for applying dry substances to inhalable pulverulent carrier substances
SE522908C2 (en) * 1999-05-10 2004-03-16 Aneo Ab Arrangements to assign a living being a anestesialt state
US6230703B1 (en) * 1999-06-02 2001-05-15 Michael Bono Aerosol inhalation device providing improved aerosol delivery
MXPA01012533A (en) 1999-06-05 2003-10-14 Innovata Biomed Ltd Delivery system.
GB2353222B (en) 1999-06-23 2001-09-19 Cambridge Consultants Inhalers
DK1808438T3 (en) * 1999-06-29 2014-10-27 Mannkind Corp Purification and stabilization of peptide and protein drugs in
US9006175B2 (en) * 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US6606992B1 (en) * 1999-06-30 2003-08-19 Nektar Therapeutics Systems and methods for aerosolizing pharmaceutical formulations
JP4932109B2 (en) 1999-07-12 2012-05-16 キャプニア インコーポレイテッド Headache, method and apparatus cure rhinitis and other common diseases
US7464706B2 (en) 1999-07-23 2008-12-16 Mannkind Corporation Unit dose cartridge and dry powder inhaler
US7305986B1 (en) 1999-07-23 2007-12-11 Mannkind Corporation Unit dose capsules for use in a dry powder inhaler
DE19942080A1 (en) * 1999-09-03 2001-03-08 Inamed Gmbh inhaler
GB9920839D0 (en) 1999-09-04 1999-11-10 Innovata Biomed Ltd Inhaler
US6235177B1 (en) 1999-09-09 2001-05-22 Aerogen, Inc. Method for the construction of an aperture plate for dispensing liquid droplets
NZ518401A (en) * 1999-10-29 2004-01-30 Nektar Therapeutics Dry powder compositions having improved dispersivity
US6367471B1 (en) * 1999-11-01 2002-04-09 Sheffield Pharmaceuticals, Inc. Internal vortex mechanism for inhaler device
US20070039615A1 (en) 1999-11-08 2007-02-22 Capnia, Incorporated Methods and apparatus for treating rhinitis
US20060172017A1 (en) 1999-11-08 2006-08-03 Capnia, Incorporated Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces
AU779413B2 (en) 1999-11-08 2005-01-20 Capnia Incorporated Method for co-application of gases and drugs to potentiate their action in relieving headaches, angina, and other ailments
US20010029947A1 (en) 1999-12-17 2001-10-18 Steve Paboojian Receptacles to facilitate the extraction of powders
US20010035184A1 (en) 1999-12-17 2001-11-01 Carlos Schuler Systems and methods for treating packaged powders
SE515473C2 (en) * 1999-12-21 2001-08-13 Cardia Innovation Ab Method and apparatus for creating a protecting atmosphere in a volume
PE08192001A1 (en) * 2000-01-10 2001-09-05 Procter & Gamble Device for dry powder inhalation
US6540982B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
ES2305057T3 (en) 2000-02-28 2008-11-01 Pharmakodex Limited Device for oral drug delivery.
US6581590B1 (en) 2000-03-21 2003-06-24 Iep Pharmaceutical Devices Inc. Inhalation actuated device
CA2826724C (en) 2000-04-11 2016-02-02 Trudell Medical International Aerosol delivery apparatus with positive expiratory pressure capacity
US6748944B1 (en) 2000-05-03 2004-06-15 Dellavecchia Michael Anthony Ultrasonic dosage device and method
US8336545B2 (en) 2000-05-05 2012-12-25 Novartis Pharma Ag Methods and systems for operating an aerosol generator
US7971588B2 (en) 2000-05-05 2011-07-05 Novartis Ag Methods and systems for operating an aerosol generator
WO2001085243A1 (en) 2000-05-05 2001-11-15 Ml Laboratories Plc Inhalation chamber
US6328035B1 (en) 2000-05-09 2001-12-11 Iep Pharmaceutical Devices Inc. Pneumatic breath actuated inhaler
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
ES2525087T5 (en) 2000-05-10 2018-06-28 Novartis Ag phospholipid based powders drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
AU5703401A (en) * 2000-05-12 2001-11-26 Dura Pharma Inc Compressed gas dry powder inhaler
US6668827B2 (en) * 2000-05-16 2003-12-30 Nektar Therapeutics Systems devices and methods for opening receptacles having a powder to be fluidized
US20020000225A1 (en) 2000-06-02 2002-01-03 Carlos Schuler Lockout mechanism for aerosol drug delivery devices
US7905230B2 (en) * 2001-05-09 2011-03-15 Novartis Ag Metered dose inhaler with lockout
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
AR028747A1 (en) * 2000-06-23 2003-05-21 Norton Health Care Ltd For deagglomerating dry powder inhaler breath actuated, dry powder inhaler and a method of deagglomerating dry powder.
TWI224515B (en) * 2000-06-23 2004-12-01 Norton Healthcare Ltd Pre-metered dose magazine for breath-actuated dry powder inhaler
US7080644B2 (en) * 2000-06-28 2006-07-25 Microdose Technologies, Inc. Packaging and delivery of pharmaceuticals and drugs
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
US6363932B1 (en) 2000-07-06 2002-04-02 Clinical Technologies, Inc. Aerosol enhancement device
US7204245B2 (en) * 2000-07-06 2007-04-17 Clinical Technologies, Inc Aerosol enhancement device
GB2364919A (en) * 2000-07-21 2002-02-13 Cambridge Consultants Inhalers
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
NZ562811A (en) 2000-08-07 2009-05-31 Centocor Inc Anti-TNF antibodies, compositions, methods and uses
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US6626168B1 (en) * 2000-08-25 2003-09-30 Corey H. Carroll Nebulizing assembly for infants
EP1351704B1 (en) 2000-12-21 2007-03-07 Nektar Therapeutics Storage stable powder compositions of interleukin-4 receptor
US6701921B2 (en) 2000-12-22 2004-03-09 Chrysalis Technologies Incorporated Aerosol generator having heater in multilayered composite and method of use thereof
US6681998B2 (en) 2000-12-22 2004-01-27 Chrysalis Technologies Incorporated Aerosol generator having inductive heater and method of use thereof
US6491233B2 (en) 2000-12-22 2002-12-10 Chrysalis Technologies Incorporated Vapor driven aerosol generator and method of use thereof
US6799572B2 (en) 2000-12-22 2004-10-05 Chrysalis Technologies Incorporated Disposable aerosol generator system and methods for administering the aerosol
US6501052B2 (en) 2000-12-22 2002-12-31 Chrysalis Technologies Incorporated Aerosol generator having multiple heating zones and methods of use thereof
US6443152B1 (en) * 2001-01-12 2002-09-03 Becton Dickinson And Company Medicament respiratory delivery device
US8221329B2 (en) * 2001-07-31 2012-07-17 The United State Of America As Represented By The Secretary Of The Army Inhalation system and method
US6904912B2 (en) * 2001-01-31 2005-06-14 The United States Of America As Represented By The Secretary Of The Army Automated inhalation toxicology exposure system
US7377276B2 (en) * 2001-01-31 2008-05-27 United States Of America As Represented By The Secretary Of The Army Automated inhalation toxicology exposure system and method
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
ZA200306564B (en) * 2001-02-26 2004-10-15 Optinose As Nasal devices.
US6546927B2 (en) 2001-03-13 2003-04-15 Aerogen, Inc. Methods and apparatus for controlling piezoelectric vibration
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
US6766799B2 (en) * 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
EP1392382B1 (en) * 2001-05-10 2008-08-06 Vectura Delivery Devices Limited Inhaler
JP4286498B2 (en) * 2002-05-14 2009-07-01 アクティヴァエロ ゲーエムベーハー Apparatus for managing the aerosol
US6631291B2 (en) * 2001-05-18 2003-10-07 Instrumentarium Corp. Closed loop drug administration method and apparatus using EEG complexity for control purposes
GB0112888D0 (en) * 2001-05-26 2001-07-18 Innovata Biomed Ltd Device
GB0114033D0 (en) * 2001-06-09 2001-08-01 Innovata Biomed Ltd Process
US7185651B2 (en) * 2002-06-18 2007-03-06 Nektar Therapeutics Flow regulator for aerosol drug delivery and methods
NZ519403A (en) * 2001-06-21 2005-03-24 Pfizer Prod Inc Use of insulin in a medicament to reduce weight gain in a diabetic patient who is using exogenous insulin to control blood sugar levels
JP2003062074A (en) * 2001-08-29 2003-03-04 Bio Media Co Ltd Aspiration unit
US6568390B2 (en) 2001-09-21 2003-05-27 Chrysalis Technologies Incorporated Dual capillary fluid vaporizing device
US6640050B2 (en) 2001-09-21 2003-10-28 Chrysalis Technologies Incorporated Fluid vaporizing device having controlled temperature profile heater/capillary tube
WO2003026559A2 (en) 2001-09-28 2003-04-03 Kurve Technology, Inc Nasal nebulizer
JP4761709B2 (en) 2002-01-15 2011-08-31 エアロジェン,インコーポレイテッド Method and system for operating an aerosol generator
JP2007528691A (en) 2001-11-14 2007-10-18 セントカー・インコーポレーテツド Anti il-6 antibody, composition, methods and uses
GB0128148D0 (en) 2001-11-23 2002-01-16 Innovata Biomed Ltd Assembly
US6804458B2 (en) 2001-12-06 2004-10-12 Chrysalis Technologies Incorporated Aerosol generator having heater arranged to vaporize fluid in fluid passage between bonded layers of laminate
US6681769B2 (en) 2001-12-06 2004-01-27 Crysalis Technologies Incorporated Aerosol generator having a multiple path heater arrangement and method of use thereof
MXPA04005865A (en) 2001-12-19 2004-09-13 Nektar Therapeutics Pulmonary delivery of aminoglycosides.
US6701922B2 (en) 2001-12-20 2004-03-09 Chrysalis Technologies Incorporated Mouthpiece entrainment airflow control for aerosol generators
JP4739672B2 (en) * 2001-12-21 2011-08-03 ネクター セラピューティクス Capsule package having a moisture barrier
US7677467B2 (en) 2002-01-07 2010-03-16 Novartis Pharma Ag Methods and devices for aerosolizing medicament
CA2472644C (en) 2002-01-07 2013-11-05 Aerogen, Inc. Devices and methods for nebulizing fluids for inhalation
JP4304077B2 (en) 2002-02-13 2009-07-29 イミュノロジー ラボラトリーズ インコーポレイテッド Compositions and methods for the treatment of microbial infections
US6651844B2 (en) 2002-02-22 2003-11-25 Schering Corporation Spray dispenser counter
US6705316B2 (en) * 2002-03-11 2004-03-16 Battelle Pulmonary Therapeutics, Inc. Pulmonary dosing system and method
EP1494732B1 (en) 2002-03-20 2008-01-30 MannKind Corporation Inhalation apparatus
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
JP4913325B2 (en) 2002-04-19 2012-04-11 スリーエム イノベイティブ プロパティズ カンパニー Spacer for inertial remove non respirable fraction of medicinal aerosol
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
DK1503788T3 (en) 2002-04-25 2011-10-17 Shire Human Genetic Therapies Treatment of Alpha-galactosidase A deficiency
US20030205226A1 (en) 2002-05-02 2003-11-06 Pre Holding, Inc. Aerosol medication inhalation system
WO2003099359A1 (en) * 2002-05-09 2003-12-04 Kurve Technology, Inc. Particle dispersion chamber for nasal nebulizer
EP1509259B1 (en) 2002-05-20 2016-04-20 Novartis AG Apparatus for providing aerosol for medical treatment and methods
US6904908B2 (en) 2002-05-21 2005-06-14 Trudell Medical International Visual indicator for an aerosol medication delivery apparatus and system
US6941980B2 (en) * 2002-06-27 2005-09-13 Nektar Therapeutics Apparatus and method for filling a receptacle with powder
JP2006504406A (en) 2002-06-28 2006-02-09 セントカー・インコーポレーテツド Mammalian ch1 deleted mimetibody, compositions, methods and uses
JP4571776B2 (en) * 2002-11-05 2010-10-27 Jx日鉱日石エネルギー株式会社 Lubricating oil compositions
US7516741B2 (en) * 2002-12-06 2009-04-14 Novartis Ag Aerosolization apparatus with feedback mechanism
WO2004054606A1 (en) * 2002-12-13 2004-07-01 Pfizer Products Inc. Method of decreasing hepatic glucose output in diabetic patients
EP1575648A4 (en) * 2002-12-18 2007-07-04 Glaxo Group Ltd Drug delivery system with vented mouthpiece
US20040206350A1 (en) * 2002-12-19 2004-10-21 Nektar Therapeutics Aerosolization apparatus with non-circular aerosolization chamber
US20050236296A1 (en) * 2002-12-30 2005-10-27 Nektar Therapeutics (Formerly Inhale Therapeutic Systems, Inc.) Carry case for aerosolization apparatus
US20040156792A1 (en) * 2002-12-31 2004-08-12 Nektar Therapeutics Pharmaceutical formulation with an insoluble active agent
US7669596B2 (en) * 2002-12-31 2010-03-02 Novartis Pharma Ag Aerosolization apparatus with rotating capsule
US20050056280A1 (en) * 2002-12-31 2005-03-17 Nektar Therapeutics Receptacle for an aerosolizable pharmaceutical formulation
US7777006B2 (en) 2002-12-31 2010-08-17 Csl Behring L.L.C. Method for purification of alpha-1-antitrypsin
EP1581182A2 (en) * 2002-12-31 2005-10-05 Nektar Therapeutics Aerosolizable pharmaceutical formulation for fungal infection therapy
US20050042170A1 (en) * 2003-02-14 2005-02-24 The Brigham And Women's Hospital, Inc. Method and device for generating mists and medical uses thereof
US8869794B1 (en) 2003-04-09 2014-10-28 Novartis Pharma Ag Aerosolization apparatus with capsule puncturing member
US7559325B2 (en) * 2003-04-09 2009-07-14 Novartis Pharma Ag Aerosolization apparatus with air inlet shield
US20070010522A1 (en) * 2003-04-09 2007-01-11 Chi Vu Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists
DK1615689T3 (en) * 2003-04-09 2016-03-14 Novartis Ag Apparatus for the formation of an aerosol and comprising an aligning guide for puncturing the capsule
US20080070932A1 (en) * 2003-04-09 2008-03-20 Chi Vu Triazolo[ 1,5-A] Pyrimidines And Pyrazolo[ 1,5-A] Pyrimidines And Methods Of Making And Using The Same
US7285550B2 (en) * 2003-04-09 2007-10-23 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines and methods of making and using the same
WO2004092177A1 (en) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
EP1633756B1 (en) * 2003-04-09 2008-12-24 Biogen Idec MA Inc. A2a adenosine receptor antagonists
US7360537B2 (en) * 2003-04-16 2008-04-22 Trudell Medical International Antistatic medication delivery apparatus
JP4742030B2 (en) 2003-04-18 2011-08-10 バイオジェン・アイデック・エムエイ・インコーポレイテッド Polymer has been linked glycosylation neublastin
US8616195B2 (en) 2003-07-18 2013-12-31 Novartis Ag Nebuliser for the production of aerosolized medication
KR20060060027A (en) 2003-08-18 2006-06-02 패리온 사이언스 인코퍼레이티드 Capped pyrazinoylguanidine sodium channel blockers
EP1673123A2 (en) * 2003-09-05 2006-06-28 Kurve Technology, Inc. Integrated nebulizer and particle dispersing chamber for delivery of medicament
WO2005023334A2 (en) * 2003-09-05 2005-03-17 Kurve Technology, Inc. Nasal adapter for the base of the nose
DE602004022571D1 (en) 2003-09-30 2009-09-24 Centocor Ortho Biotech Inc Human epo mimetic nuclear-mimetikörper, compositions, methods and applications
US7338171B2 (en) * 2003-10-27 2008-03-04 Jen-Chuen Hsieh Method and apparatus for visual drive control
WO2005040163A1 (en) * 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd Heterocyclic compounds that block the effects of advanced glycation end products (age)
US20050214224A1 (en) * 2003-11-04 2005-09-29 Nektar Therapeutics Lipid formulations for spontaneous drug encapsulation
US7192919B2 (en) * 2004-01-07 2007-03-20 Stelios Tzannis Sustained release compositions for delivery of pharmaceutical proteins
KR100985126B1 (en) * 2004-01-12 2010-10-05 맨카인드 코포레이션 A method of reducing serum proinsulin levels in type 2 diabetics
BRPI0507397A (en) * 2004-02-06 2007-07-10 Microdose Technologies Inc packaging for use with gallbladder in an inhalation device
US7107987B2 (en) * 2004-02-10 2006-09-19 Cfd Research Corporation Spacer for delivery of medications from an inhaler to children and breathing impaired patients
WO2005079755A2 (en) * 2004-02-12 2005-09-01 Nektar Therapeutics Interleukin-13 antagonist powders, spray-dried particles, and methods
CN100589849C (en) 2004-02-24 2010-02-17 微计量技术有限公司 Synthetic jet based medicament delivery method and apparatus
MXPA06009516A (en) 2004-02-24 2007-03-26 Microdose Technologies Inc Directional flow sensor inhaler.
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
WO2005097175A2 (en) 2004-03-31 2005-10-20 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses
GB0407472D0 (en) * 2004-04-01 2004-05-05 Dvm Pharmaceuticals Inc Small animal mask
US7946291B2 (en) 2004-04-20 2011-05-24 Novartis Ag Ventilation systems and methods employing aerosol generators
WO2005102429A1 (en) * 2004-04-21 2005-11-03 Innovata Biomed Limited Inhaler
GB0409197D0 (en) 2004-04-24 2004-05-26 Innovata Biomed Ltd Device
US7611709B2 (en) * 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US7727962B2 (en) * 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
US7723306B2 (en) * 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
KR20070026604A (en) 2004-06-18 2007-03-08 네크타르 테라퓨틱스 Methods of treatment of endobronchial infections
WO2006002140A2 (en) * 2004-06-21 2006-01-05 Nektar Therapeutics Compositions comprising amphotericin b
US8513204B2 (en) * 2004-06-21 2013-08-20 Novartis Ag Compositions comprising amphotericin B, mehods and systems
CN103223160B (en) 2004-07-19 2015-02-18 比奥孔有限公司 Cation complexes of insulin compund conjugates, formulation and uses thereof
JP4959566B2 (en) * 2004-08-19 2012-06-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド Transforming growth factor β family protein folding
GEP20115196B (en) * 2004-08-19 2011-04-11 Biogen Idec Inc Neublastin variants
AU2005277208B2 (en) 2004-08-20 2011-11-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
DK2322180T3 (en) 2004-08-23 2015-06-15 Mannkind Corp Diketopiperazinsalte for drug delivery
US7393662B2 (en) * 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
GB0427028D0 (en) * 2004-12-09 2005-01-12 Cambridge Consultants Dry powder inhalers
DE102005016102B3 (en) * 2005-04-08 2006-10-26 Altana Pharma Ag Device for dosing and dry nebulization
TW200716751A (en) 2005-04-11 2007-05-01 Savient Pharmaceuticals Inc A variant form of urate oxidase and use thereof
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
ES2538357T3 (en) 2005-04-11 2015-06-19 Crealta Pharmaceuticals Llc variant forms urate oxidase and use thereof
JO3058B1 (en) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc Anti-IL-6 Antibodies,Compositions,Methods and uses
US8546423B2 (en) 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
AU2006247053B2 (en) 2005-05-18 2013-05-23 Horizon Orphan Llc Aerosolized fluoroquinolones and uses thereof
US20090081122A1 (en) * 2005-05-23 2009-03-26 Universite De Geneve Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant
CA2607747C (en) 2005-05-25 2015-12-01 Aerogen, Inc. Vibration systems and methods
ES2410406T3 (en) 2005-06-30 2013-07-01 Janssen Biotech, Inc. anti-IL-23 compositions, methods and uses Antibodies
ES2611307T3 (en) 2005-08-30 2017-05-08 University Of Miami Immunomodulation of agonists, antagonists and immunotoxins receptor tumor necrosis factor 25 (TNFR25)
KR20120060245A (en) 2005-09-14 2012-06-11 맨카인드 코포레이션 Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
AU2007238114B2 (en) 2006-04-12 2010-10-14 Biodel, Inc. Rapid acting and long acting insulin combination formulations
WO2007041481A1 (en) * 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
AU2006297394B9 (en) * 2005-09-29 2013-09-19 Novartis Ag Receptacles and kits, such as for dry powder packaging
ES2390286T3 (en) 2005-12-16 2012-11-08 Nektar Therapeutics Polymer conjugates of GLP-1
EP2548577B1 (en) 2005-12-29 2017-02-15 Janssen Biotech, Inc. Human anti-il-23 antibodies, compositions, methods and uses
US7681569B2 (en) * 2006-01-23 2010-03-23 Lytesyde, Llc Medical liquid processor apparatus and method
US7717096B2 (en) * 2006-01-23 2010-05-18 Lytesyde, Llc Fuel processor apparatus and method
DE102006007495A1 (en) * 2006-02-17 2007-08-23 Siegfried Generics International Ag Dispersion unit e.g. for medical powder inhalator and aerosol dispersion, uses annular guide chamber to direct entering powder flow in mainly radial direction
JP5599975B2 (en) 2006-02-22 2014-10-01 マンカインド コーポレイション Method for improving the formulation properties of the fine particles containing diketopiperazine and an active agent
WO2007103182A2 (en) * 2006-03-01 2007-09-13 Biogen Idec Ma Inc. Compostions and methods for administering gdnf ligand family proteins
CN101437562A (en) * 2006-03-03 2009-05-20 Stc.Unm公司 Dry powder inhaler with aeroelastic dispersion mechanism
EP2001535A1 (en) 2006-03-21 2008-12-17 Bang & Olufsen Medicom A/S Inhaler flow channel
CA2648035A1 (en) * 2006-03-31 2007-10-11 Centocor, Inc. Human epo mimetic hinge core mimetibodies, compositions, methods and uses for preventing or treating glucose intolerance related conditions or renal disease associated anemia
EP2357015A3 (en) 2006-04-05 2012-07-25 MicroDose Therapeutx, Inc. Variable dose inhalation device
PT2001537E (en) * 2006-04-05 2011-05-11 Microdose Therapeutx Inc Variable dose inhalation device
WO2008051178A2 (en) * 2006-04-12 2008-05-02 Savient Pharmaceuticals, Inc. Purification of proteins with cationic surfactant
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
FR2901144B1 (en) * 2006-05-16 2008-12-26 Diffusion Tech Francaise Sarl Apparatus for medical aerosol generator including a device for improving the efficiency of deposition of aerosol
CA2698137A1 (en) 2006-08-30 2008-03-06 Kurve Technology, Inc. Aerosol generating and delivery device
US20080087279A1 (en) * 2006-10-11 2008-04-17 Tieck Catharine Laureen Johnso Metered dose inhaler
AR064623A1 (en) * 2006-12-21 2009-04-15 Centocor Inc Using receptor agonists glp -1 prolonged action to improve insulin sensitivity and lipid profiles
US20080163610A1 (en) * 2007-01-05 2008-07-10 Matthew Thomas Baird Method and system for regenerating exhaust system filtering and catalyst components using variable high engine idle
EP2425819A1 (en) 2007-02-11 2012-03-07 MAP Pharmaceuticals Inc Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
US8237558B2 (en) 2007-03-30 2012-08-07 University Health Network Hand hygiene compliance system
US7898407B2 (en) 2007-03-30 2011-03-01 Toronto Rehabilitation Institute Hand hygiene compliance system
WO2008124522A2 (en) * 2007-04-04 2008-10-16 Biodel, Inc. Amylin formulations
JP5583005B2 (en) 2007-05-01 2014-09-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド Compositions and methods for increasing angiogenesis
US20100263666A1 (en) * 2007-05-23 2010-10-21 Ryoichi Nagata Test substance administration system for animal experiment
JP4916954B2 (en) * 2007-05-30 2012-04-18 株式会社吉野工業所 Aspirating doser
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US8415390B2 (en) 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
AU2008259768B2 (en) * 2007-06-05 2013-08-29 Paka Pulmonary Pharmaceuticals, Inc. Compositions for delivering medicaments into the lungs, uses thereof
US8496002B2 (en) 2007-06-12 2013-07-30 Civitas Therapeutics, Inc. Powder inhaler devices
EP2173419A4 (en) * 2007-06-28 2016-07-27 Inhalation Sciences Sweden Ab Exposure system
DK2898914T3 (en) 2007-07-06 2018-09-03 Manta Devices Llc Inhalation devices for storage and delivery of medicament
US8181651B2 (en) * 2007-07-24 2012-05-22 Passy-Muir, Inc. Hand powered suction device with mucus trap and suction catheter for tracheostomy tubes
EP2020249A1 (en) 2007-08-01 2009-02-04 Boehringer Ingelheim Pharma GmbH & Co. KG Inhalator
US8028674B2 (en) * 2007-08-07 2011-10-04 Lytesyde, Llc Fuel processor apparatus and method
WO2009020964A2 (en) * 2007-08-08 2009-02-12 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
CN103408658A (en) 2007-08-17 2013-11-27 Csl百灵有限公司 Methods for purification of alpha-1-antitrypsin and apolipoprotein A-I
US20090056716A1 (en) * 2007-09-04 2009-03-05 Atlantic Research Group Llc Cool air inhaler and methods of treatment using same
EP2207890A4 (en) 2007-10-05 2010-12-15 Barofold Inc High pressure treatment of aggregated interferons
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
EP2207584A2 (en) * 2007-10-25 2010-07-21 Novartis Ag Powder conditioning of unit dose drug packages
HUE027246T2 (en) 2008-01-24 2016-10-28 Vectura Delivery Devices Ltd Inhaler
TWI432198B (en) 2008-02-26 2014-04-01 Parion Sciences Inc Poly aromatic sodium channel blockers
US8371294B2 (en) * 2008-02-29 2013-02-12 Microdose Therapeutx, Inc. Method and apparatus for driving a transducer of an inhalation device
RU2491103C2 (en) * 2008-03-27 2013-08-27 Маннкайнд Корпорейшн Dry powder inhalation system
BRPI0913021A2 (en) * 2008-05-15 2015-10-13 Novartis Ag pulmonary delivery of a fluoroquinolone
DK2570147T3 (en) 2008-06-13 2018-01-29 Mannkind Corp Dry powder inhaler and system for drug administration
RU2470681C2 (en) 2008-06-20 2012-12-27 Маннкайнд Корпорейшн Interactive system and method for real-time force profiling in inhalation
WO2010008523A1 (en) 2008-07-13 2010-01-21 Map Pharmaceuticals, Inc. Methods and apparatus for delivering aerosolized medication
TWI614024B (en) 2008-08-11 2018-02-11 Mannkind Corp Use of ultrarapid acting insulin
MY153074A (en) 2008-08-14 2014-12-31 Teva Pharmaceuticals Australia Pty Ltd Anti-il-12/11-23 antibodies
US20110105383A1 (en) * 2008-09-10 2011-05-05 Magnus Hook Methods and compositions for stimulation of mammalian innate immune resistance to pathogens
EP2350118B1 (en) 2008-09-19 2016-03-30 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
WO2010033220A2 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
JP2012505223A (en) 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド Aerosol fluoroquinolone formulations for improving the pharmacokinetics
WO2010042549A1 (en) 2008-10-07 2010-04-15 Mpex Pharmaceuticals, Inc. Inhalation of levofloxacin for reducing lung inflammation
PT2356269T (en) 2008-10-31 2016-09-13 Janssen Biotech Inc Fibronectin type iii domain based scaffold compositions, methods and uses
WO2010068754A2 (en) 2008-12-10 2010-06-17 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of medicaments to the lungs
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
WO2010083042A1 (en) * 2009-01-15 2010-07-22 Manta Devices, Llc Delivery device
RU2562700C2 (en) 2009-02-12 2015-09-10 Янссен Байотек, Инк. Compositions, methods of producing and using fibronectin type iii domain based scaffold
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
DK2405963T3 (en) 2009-03-11 2013-12-16 Mannkind Corp An apparatus, system and method for measuring resistance in an inhaler
CA2755809C (en) 2009-03-18 2014-02-18 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
ES2534947T3 (en) 2009-03-25 2015-04-30 The Board Of Regents Of The University Of Texas System Compositions for stimulating innate immune resistance mammalian pathogen
CA2757500A1 (en) 2009-04-01 2010-10-07 Promedior, Inc. Pulmonary and nasal delivery of serum amyloid p
US8985101B2 (en) 2009-05-21 2015-03-24 Microdose Therapeutx, Inc. Method and device for clamping a blister within a dry powder inhaler
BRPI1011194A2 (en) * 2009-05-21 2016-12-27 Microdose Therapeutx Inc rotating container system for dry powder inhaler
WO2010142017A1 (en) 2009-06-09 2010-12-16 Defyrus, Inc . Administration of interferon for prophylaxis against or treatment of pathogenic infection
BRPI1013154A2 (en) 2009-06-12 2016-04-05 Mannkind Corp microparticles of diketopiperazine with specific surface areas defined.
CZ20110827A3 (en) 2009-06-25 2012-09-26 Savient Pharmaceuticals, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
US9180263B2 (en) * 2009-07-01 2015-11-10 Microdose Therapeutx, Inc. Laboratory animal pulmonary dosing device
US20110000481A1 (en) * 2009-07-01 2011-01-06 Anand Gumaste Nebulizer for infants and respiratory compromised patients
US20120114554A1 (en) 2009-07-13 2012-05-10 Liquidia Technologies, Inc. Engineered Aerosol Particles, And Associated Methods
GB0914738D0 (en) * 2009-08-24 2009-09-30 Cambridge Consultants Inhalers
RU2015130524A (en) 2009-09-04 2018-12-21 Раптор Фармасьютикалз Инк. Application of levofloxacin in aerosol form for the treatment of cystic fibrosis
WO2011035140A1 (en) 2009-09-18 2011-03-24 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of contrast moieties to the lungs
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
CA2779488A1 (en) 2009-11-12 2011-05-19 Stc.Unm Dry powder inhaler with flutter dispersion member
WO2011066107A1 (en) 2009-11-24 2011-06-03 Gilead Sciences, Inc. Inhaled fosfomycin/tobramycin for the treatment of chronic obstructive pulmonary disease
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
EP3431128A1 (en) 2010-01-05 2019-01-23 MicroDose Therapeutx, Inc. Inhalation device and method
CN102933231B (en) 2010-02-10 2015-07-29 伊缪诺金公司 Cd20 antibody and uses thereof
WO2011116293A2 (en) 2010-03-19 2011-09-22 Manta Devices, Llc Delivery device and related methods
GB201006480D0 (en) * 2010-04-19 2010-06-02 Intersurgical Ag Improvements relating to respiratory apparatus
CN102869402A (en) * 2010-04-23 2013-01-09 3M创新有限公司 Dry powder inhaler assembly and containers
NZ603136A (en) 2010-05-10 2014-11-28 Gilead Sciences Inc Bifunctional quinoline derivatives
WO2011143106A1 (en) 2010-05-10 2011-11-17 Gilead Sciences, Inc. Bi - functional pyrazolopyridine compounds
AU2011268110B2 (en) 2010-06-19 2016-05-19 Memorial Sloan-Kettering Cancer Center Anti-GD2 antibodies
AU2011271097B2 (en) 2010-06-21 2014-11-27 Mannkind Corporation Dry powder drug delivery system and methods
HUE029174T2 (en) 2010-06-24 2017-02-28 Gilead Sciences Inc Pyrazolo[1,5-a]pyrimidines and -triazines as antiviral agents
JP5969471B2 (en) 2010-07-22 2016-08-17 ギリード・サイエンシズ・インコーポレーテッド The methods and compounds for treating Paramyxoviridae virus infection
TW201305185A (en) 2010-09-13 2013-02-01 Gilead Sciences Inc 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
ES2646748T3 (en) 2010-12-07 2017-12-15 Respira Therapeutics, Inc. Dry powder inhaler
EP2661254B1 (en) 2011-01-05 2017-08-02 Hospira, Inc. Spray drying vancomycin
WO2012154483A1 (en) 2011-05-06 2012-11-15 Gilead Sciences, Inc. Dry powder fosfomycin/tobramycin formulation for inhalation
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
WO2012175735A1 (en) 2011-06-23 2012-12-27 Vib Vzw A20 inhibitors for the treatment of respiratory viral infections
SI2723176T1 (en) 2011-06-27 2017-09-29 Parion Sciences, Inc. A chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity
AR086745A1 (en) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-chloro-n- (n- (4- (4- (2- (hexyl (2,3,4,5,6-pentahydroxyhexyl) amino) ethoxy) phenyl) butyl) carbamimidoyl) pyrazine -2-carboxamide
JP2014518270A (en) * 2011-06-27 2014-07-28 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム Toroidal pharmaceutical preparations
AU2012328885B2 (en) 2011-10-24 2017-08-31 Mannkind Corporation Methods and compositions for treating pain
US9603907B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Dry powder formulations of dNase I
MX355267B (en) * 2012-03-13 2018-04-12 Gilead Sciences Inc 2'- substituted carba-nucleoside analogs for antiviral treatment.
US10086007B2 (en) 2012-04-05 2018-10-02 University Of Florida Research Foundation, Incorporated Materials and methods for treatment of cystic fibrosis and for induction of ion secretion
NZ701647A (en) 2012-04-17 2016-05-27 Gilead Sciences Inc Compounds and methods for antiviral treatment
US9649454B2 (en) 2012-05-03 2017-05-16 Manta Devices, Llc Delivery device and related methods
RU2014151570A (en) * 2012-05-22 2016-07-10 Конинклейке Филипс Н.В. The system and method of maintaining pressure therapy using specific airflow shape
TR201809148T4 (en) 2012-05-29 2018-07-23 Parion Sciences Inc Dry eye and other sodium channel blockers for the treatment of mucosal diseases with dendrimer-like activity amino acids.
SG11201500218VA (en) 2012-07-12 2015-03-30 Mannkind Corp Dry powder drug delivery systems and methods
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
EP3278805A1 (en) 2012-10-31 2018-02-07 Galecto Biotech AB Diagnosing pulmonary fibrosis
CN102961809A (en) * 2012-11-15 2013-03-13 王路维 Respiration synchronizing air compression type atomizer device
ES2674665T3 (en) 2012-12-17 2018-07-03 Parion Sciences, Inc. Compounds 3,5-diamino-6-chloro-N- (N- (4-phenylbutyl) carbamimidoyl) pyrazine-2-carboxamide
CN108658876A (en) 2012-12-17 2018-10-16 帕里昂科学公司 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds
LT2931713T (en) 2012-12-17 2017-02-10 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
US20160010043A9 (en) * 2013-02-12 2016-01-14 37 Investment, LLC Alcohol Evaporation Consumption Device
BR112015021931A8 (en) 2013-03-11 2018-01-23 Univ Florida uses of pharmaceutical compositions for the prevention and / or treatment of lung complications and radiation-induced pulmonary function
CN104043104B (en) 2013-03-15 2018-07-10 浙江创新生物有限公司 Dry and spray-containing industrial preparation of vancomycin hydrochloride
EP2781232A1 (en) * 2013-03-21 2014-09-24 Ca-Mi S.R.L. Device for facilitating the inhalation of medicinal products
CA2918369A1 (en) 2013-07-18 2015-01-22 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
EP2868339B1 (en) * 2013-11-04 2016-10-19 Stamford Devices Limited An aerosol delivery system
US10092712B2 (en) 2013-11-04 2018-10-09 Stamford Devices Limited Aerosol delivery system
JP2017502064A (en) 2014-01-10 2017-01-19 ジェノア ファーマシューティカルズ,インク. Compound analog pirfenidone and pyridone aerosol, and the use thereof
WO2015143012A1 (en) 2014-03-19 2015-09-24 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015179369A1 (en) 2014-05-20 2015-11-26 Infinity Pharmaceuticals, Inc. Treatment of pulmonary or respiratory diseases by inhalation administration of pi3 kinase inhibitors
CN106573120A (en) 2014-07-07 2017-04-19 微剂量治疗公司 Inhalation device
TW201617350A (en) 2014-07-28 2016-05-16 Gilead Sciences Inc Thieno[3,2-d]pyrimidine, furo[3,2-d]pyrimidine, and pyrrolo[3,2-d]pyrimidines useful for treating respiratory syncitial virus infections
US20170304459A1 (en) 2014-10-10 2017-10-26 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhalation delivery of conjugated oligonucleotide
EP3244914A4 (en) 2015-01-16 2018-08-15 The J. David Gladstone Institutes Methods for treating tauopathy
WO2017145046A1 (en) * 2016-02-25 2017-08-31 Sabic Global Technologies B.V. Dust aerosols generating chamber
AU2017296237A1 (en) 2016-07-15 2019-01-03 Poseida Therapeutics, Inc. Chimeric antigen receptors (CARS) specific for MUC1 and methods for their use
AU2017296236A1 (en) 2016-07-15 2019-01-03 Poseida Therapeutics, Inc. Chimeric antigen receptors and methods for use
CA3028551A1 (en) * 2016-07-28 2018-02-01 Chiesi Farmaceutici S.P.A. Method and system for delivery of an aerosolized medicament
WO2018071443A1 (en) 2016-10-11 2018-04-19 Microdose Therapeutx, Inc. Inhaler and methods of use thereof
WO2018140026A1 (en) 2017-01-27 2018-08-02 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules

Citations (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US487744A (en) * 1892-12-13 Self-lighting gas-burner
US513189A (en) * 1894-01-23 Powder-blower
US2549303A (en) * 1949-04-20 1951-04-17 Bristol Lab Inc Inhaler for crystalline pencilllin or the like
US2570774A (en) * 1947-10-21 1951-10-09 Frank P C Davis Insufflator
US2598525A (en) * 1950-04-08 1952-05-27 E & J Mfg Co Automatic positive pressure breathing machine
US2603216A (en) * 1952-07-15 Powder inhaler
US3362405A (en) * 1964-04-06 1968-01-09 Hamilton O. Hazel Method and apparatus for admixing gas with solid particles
US3425600A (en) * 1966-08-11 1969-02-04 Abplanalp Robert H Pressurized powder dispensing device
US3809084A (en) * 1970-02-16 1974-05-07 American Cyanamid Co Pressurized portable dispenser
US3812854A (en) * 1972-10-20 1974-05-28 A Michaels Ultrasonic nebulizer
US3918451A (en) * 1973-09-18 1975-11-11 Ritzau Pari Werk Kg Paul Inhalator for pulverulent substances
US3921637A (en) * 1973-07-23 1975-11-25 Bespak Industries Ltd Inhaler for powdered medicament
US3964483A (en) * 1975-01-13 1976-06-22 Syntex Puerto Rico, Inc. Inhalation device
US3967761A (en) * 1974-04-08 1976-07-06 Southwest Research Institute System for injecting particulate material into the combustion chamber of a repetitive combustion coating apparatus
US3991304A (en) * 1975-05-19 1976-11-09 Hillsman Dean Respiratory biofeedback and performance evaluation system
US3991761A (en) * 1974-03-18 1976-11-16 Salvatore Cocozza Inhaler for powdered medicaments
US3994421A (en) * 1975-09-29 1976-11-30 American Cyanamid Company Unitary therapeutic aerosol dispenser
US4017007A (en) * 1973-12-26 1977-04-12 Ciba-Geigy Corporation Single dose air pressure operated dispenser
US4018185A (en) * 1975-12-15 1977-04-19 Coors Container Company Powder feeder pick-up tube
US4022224A (en) * 1975-09-09 1977-05-10 Diagnostic Data, Inc. Reduction of superoxide accumulation caused by smoke inhalation
US4036223A (en) * 1975-01-29 1977-07-19 Obert Jean Claude Apparatus for generating aerosols of solid particles
US4046146A (en) * 1974-08-22 1977-09-06 Schering Aktiengesellschaft Apparatus for the inhalation of medicinal agents
US4069819A (en) * 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
US4098273A (en) * 1975-01-13 1978-07-04 Syntex Puerto Rico, Inc. Inhalation device
US4105027A (en) * 1975-06-13 1978-08-08 Syntex Puerto Rico, Inc. Inhalation device
US4109656A (en) * 1977-02-07 1978-08-29 Sybron Corporation Apparatus for use with insufflators
US4114615A (en) * 1975-12-12 1978-09-19 Aktiebolaget Draco Aerosol inhalation device
US4174712A (en) * 1976-11-09 1979-11-20 Aktiebolaget Draco Device for use with medicinal inhalation devices
US4249526A (en) * 1978-05-03 1981-02-10 Fisons Limited Inhalation device
US4253468A (en) * 1978-08-14 1981-03-03 Steven Lehmbeck Nebulizer attachment
US4338931A (en) * 1979-04-27 1982-07-13 Claudio Cavazza Device for the quick inhalation of drugs in powder form by humans suffering from asthma
US4396152A (en) * 1977-03-02 1983-08-02 Abplanalp Robert H Aerosol dispenser system
US4423724A (en) * 1980-06-06 1984-01-03 Fisons Limited Inhalation device for powdered medicaments
US4446862A (en) * 1979-10-30 1984-05-08 Baum Eric A Breath actuated devices for administering powdered medicaments
US4452239A (en) * 1980-03-25 1984-06-05 Hilal Malem Medical nebulizing apparatus
US4470412A (en) * 1982-03-19 1984-09-11 Trutek Research, Inc. Inhalation valve
US4484577A (en) * 1981-07-23 1984-11-27 Key Pharmaceuticals, Inc. Drug delivery method and inhalation device therefor
US4534343A (en) * 1984-01-27 1985-08-13 Trutek Research, Inc. Metered dose inhaler
US4570630A (en) * 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
US4624251A (en) * 1984-09-13 1986-11-25 Riker Laboratories, Inc. Apparatus for administering a nebulized substance
US4649911A (en) * 1983-09-08 1987-03-17 Baylor College Of Medicine Small particle aerosol generator for treatment of respiratory disease including the lungs
US4668218A (en) * 1985-04-12 1987-05-26 Aktiebolaget Draco Indicating means for a dosage dispensing device
US4674491A (en) * 1984-08-09 1987-06-23 Inge Brugger Inhaler
US4677975A (en) * 1984-10-16 1987-07-07 The University Of Auckland Method of dispensing and/or a dispenser
US4739754A (en) * 1986-05-06 1988-04-26 Shaner William T Suction resistant inhalator
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
US4796614A (en) * 1987-02-26 1989-01-10 Trutek Research, Inc. Collapsible inhalation valve
US4807814A (en) * 1985-01-04 1989-02-28 Saint Gobain Vitrage Pneumatic powder ejector
US4811731A (en) * 1985-07-30 1989-03-14 Glaxo Group Limited Devices for administering medicaments to patients
US4819629A (en) * 1986-10-28 1989-04-11 Siemens Aktiengesellschaft Method and apparatus for delivering aerosol to the airways and/or lungs of a patient
US4823784A (en) * 1982-04-30 1989-04-25 Cadema Medical Products, Inc. Aerosol inhalation apparatus
US4852561A (en) * 1988-07-27 1989-08-01 Sperry C R Inhalation device
US4860740A (en) * 1980-10-30 1989-08-29 Riker Laboratories, Inc. Powder inhalation device
US4884114A (en) * 1982-08-18 1989-11-28 Siemens Aktiengesellschaft Disconnectable thyristor
US4907583A (en) * 1986-03-07 1990-03-13 Aktiebolaget Draco Device in powder inhalators
US4926852A (en) * 1986-06-23 1990-05-22 The Johns Hopkins University Medication delivery system phase one
US4942544A (en) * 1985-02-19 1990-07-17 Kenneth B. McIntosh Medication clock
US4984158A (en) * 1988-10-14 1991-01-08 Hillsman Dean Metered dose inhaler biofeedback training and evaluation system
US4986269A (en) * 1985-05-23 1991-01-22 Etela-Hameen Keuhkovammayhdistys R.Y. Respiration therapy apparatus
US4995385A (en) * 1989-02-23 1991-02-26 Phidea S.P.A. Inhaler with regular complete emptying of the capsule
US5020527A (en) * 1990-02-20 1991-06-04 Texax-Glynn Corporation Inhaler device with counter/timer means
US5027806A (en) * 1988-10-04 1991-07-02 The Johns Hopkins University Medication delivery system phase two
US5033463A (en) * 1989-10-27 1991-07-23 Miat S.P.A. Multi-dose inhaler for medicaments in powder form
US5048514A (en) * 1989-07-07 1991-09-17 Somova S.P.A. Inhaler for medicaments contained in capsules
US5099833A (en) * 1991-02-19 1992-03-31 Baxter International Inc. High efficiency nebulizer having a flexible reservoir
US5112598A (en) * 1988-05-04 1992-05-12 Hermes Fabrik Pharmazeutischer Preparate Franz Gradinger Gmbh & Co. Kg Vitamin a aerosol-inhalate preparations
US5113855A (en) * 1990-02-14 1992-05-19 Newhouse Michael T Powder inhaler
US5161524A (en) * 1991-08-02 1992-11-10 Glaxo Inc. Dosage inhalator with air flow velocity regulating means
US5186166A (en) * 1992-03-04 1993-02-16 Riggs John H Powder nebulizer apparatus and method of nebulization
US5186164A (en) * 1991-03-15 1993-02-16 Puthalath Raghuprasad Mist inhaler
US5201308A (en) * 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
US5207217A (en) * 1990-07-16 1993-05-04 Promo Pack Sa Multiple single-dose inhaler for medicaments in powder form
US5250287A (en) * 1991-06-14 1993-10-05 Miat S.P.A. Multi-dose insufflator for medicaments in powder form
US5284133A (en) * 1992-07-23 1994-02-08 Armstrong Pharmaceuticals, Inc. Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means
US5295479A (en) * 1991-04-15 1994-03-22 Leiras Oy Device intended for measuring a dose of powdered medicament for inhalation
US5309900A (en) * 1991-03-21 1994-05-10 Paul Ritzau Pari-Werk Gmbh Atomizer particularly for use in devices for inhalation therapy
US5320714A (en) * 1990-02-16 1994-06-14 Byk Gulden Lomberg Chemische Fabrik Gmbh Powder inhalator
US5331953A (en) * 1989-03-07 1994-07-26 Aktiebolaget Draco Device in connection with an inhaler
US5337740A (en) * 1991-08-01 1994-08-16 New England Pharmaceuticals, Inc. Inhalation devices
US5349947A (en) * 1993-07-15 1994-09-27 Newhouse Michael T Dry powder inhaler and process that explosively discharges a dose of powder and gas from a soft plastic pillow
US5355872A (en) * 1992-03-04 1994-10-18 Riggs John H Low flow rate nebulizer apparatus and method of nebulization
US5363842A (en) * 1991-12-20 1994-11-15 Circadian, Inc. Intelligent inhaler providing feedback to both patient and medical professional
US5366122A (en) * 1991-08-27 1994-11-22 Ing. Erich Pfeiffer Gmbh & Co. Kg Dispenser for flowable media
US5404871A (en) * 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
US5458135A (en) * 1991-07-02 1995-10-17 Inhale Therapeutic Systems Method and device for delivering aerosolized medicaments
US5522383A (en) * 1990-06-14 1996-06-04 Rhone-Poulenc Rorer Ltd. Powder inhaler having capsule holding structure and anti-static walls
US5645050A (en) * 1991-12-20 1997-07-08 Boehringer Ingelheim Kg Powder inhaler with powder carrier consisting of regular microstructures
US5740794A (en) * 1994-09-21 1998-04-21 Inhale Therapeutic Systems Apparatus and methods for dispersing dry powder medicaments
US5755221A (en) * 1990-09-12 1998-05-26 Bisgaard; Hans Aerosol inhaler with piston dump
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US5983893A (en) * 1994-12-21 1999-11-16 Astra Aktiebolag Inhalation device
US6029661A (en) * 1991-08-26 2000-02-29 3M Innovative Properties Company Powder dispenser
US6116237A (en) * 1996-04-29 2000-09-12 Dura Pharmaceuticals, Inc. Methods of dry powder inhalation
US6681767B1 (en) * 1991-07-02 2004-01-27 Nektar Therapeutics Method and device for delivering aerosolized medicaments

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2533065A (en) * 1947-03-08 1950-12-05 George V Taplin Micropulverized therapeutic agents
FR2257351B1 (en) * 1974-01-11 1978-03-24 Obert Jean Claude
GB2063075B (en) * 1979-11-07 1983-11-09 Sterwin Ag Dose indicator for inhalers
DE3023648A1 (en) * 1980-06-24 1982-01-21 Jaeger Erich Device for examination of the airway to irritating substances-over sensitivity
WO1985002346A1 (en) * 1983-11-28 1985-06-06 Vortran Corporation Gas-powered nebulizer
FI76929C (en) * 1984-09-25 1989-01-10 Etelae Haemeen Keuhkovammayhdi Inhalationsdoseringsanordning, som aer avsedd Foer nogrann dosering of disponerande laekemedel som i ges AOT andningssjuka undersoekningsskedet and / or laekemedel som ges som spray during the treatment.
NZ219021A (en) * 1986-01-27 1989-06-28 Gea Farmaceutisk Fabrik As Inhaler: medicine discharged intermittently during each inhalation
FR2598918B1 (en) * 1986-05-23 1988-08-05 Lille Ii Universite Droit Sant A device for insufflation into the respiratory tract of a radiopaque powder has the state finely divided
US4790305A (en) * 1986-06-23 1988-12-13 The Johns Hopkins University Medication delivery system
IT1217890B (en) 1988-06-22 1990-03-30 Chiesi Farma Spa Device for inhalation of MDIs
DK479189D0 (en) 1989-01-06 1989-09-28 Hans Gernot Schenk inhaler
GB8908647D0 (en) * 1989-04-17 1989-06-01 Glaxo Group Ltd Device
FI84698C (en) * 1989-06-16 1992-01-10 Huhtamaeki Oy An apparatus Foer finfoerdelning of agglomerat of a enkeldos of a laekemedelpreparat i pulverform.
GB9027234D0 (en) * 1990-12-15 1991-02-06 Harris Pharma Ltd An inhalation device
GB9106648D0 (en) * 1991-03-28 1991-05-15 Rhone Poulenc Rorer Ltd New inhaler

Patent Citations (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US487744A (en) * 1892-12-13 Self-lighting gas-burner
US513189A (en) * 1894-01-23 Powder-blower
US2603216A (en) * 1952-07-15 Powder inhaler
US2570774A (en) * 1947-10-21 1951-10-09 Frank P C Davis Insufflator
US2549303A (en) * 1949-04-20 1951-04-17 Bristol Lab Inc Inhaler for crystalline pencilllin or the like
US2598525A (en) * 1950-04-08 1952-05-27 E & J Mfg Co Automatic positive pressure breathing machine
US3362405A (en) * 1964-04-06 1968-01-09 Hamilton O. Hazel Method and apparatus for admixing gas with solid particles
US3425600A (en) * 1966-08-11 1969-02-04 Abplanalp Robert H Pressurized powder dispensing device
US3809084A (en) * 1970-02-16 1974-05-07 American Cyanamid Co Pressurized portable dispenser
US3812854A (en) * 1972-10-20 1974-05-28 A Michaels Ultrasonic nebulizer
US4069819A (en) * 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
US3921637A (en) * 1973-07-23 1975-11-25 Bespak Industries Ltd Inhaler for powdered medicament
US3918451A (en) * 1973-09-18 1975-11-11 Ritzau Pari Werk Kg Paul Inhalator for pulverulent substances
US4017007A (en) * 1973-12-26 1977-04-12 Ciba-Geigy Corporation Single dose air pressure operated dispenser
US3991761A (en) * 1974-03-18 1976-11-16 Salvatore Cocozza Inhaler for powdered medicaments
US3967761A (en) * 1974-04-08 1976-07-06 Southwest Research Institute System for injecting particulate material into the combustion chamber of a repetitive combustion coating apparatus
US4046146A (en) * 1974-08-22 1977-09-06 Schering Aktiengesellschaft Apparatus for the inhalation of medicinal agents
US4098273A (en) * 1975-01-13 1978-07-04 Syntex Puerto Rico, Inc. Inhalation device
US3964483A (en) * 1975-01-13 1976-06-22 Syntex Puerto Rico, Inc. Inhalation device
US4036223A (en) * 1975-01-29 1977-07-19 Obert Jean Claude Apparatus for generating aerosols of solid particles
US3991304A (en) * 1975-05-19 1976-11-09 Hillsman Dean Respiratory biofeedback and performance evaluation system
US4105027A (en) * 1975-06-13 1978-08-08 Syntex Puerto Rico, Inc. Inhalation device
US4022224A (en) * 1975-09-09 1977-05-10 Diagnostic Data, Inc. Reduction of superoxide accumulation caused by smoke inhalation
US3994421A (en) * 1975-09-29 1976-11-30 American Cyanamid Company Unitary therapeutic aerosol dispenser
US4114615A (en) * 1975-12-12 1978-09-19 Aktiebolaget Draco Aerosol inhalation device
US4018185A (en) * 1975-12-15 1977-04-19 Coors Container Company Powder feeder pick-up tube
US4174712A (en) * 1976-11-09 1979-11-20 Aktiebolaget Draco Device for use with medicinal inhalation devices
US4109656A (en) * 1977-02-07 1978-08-29 Sybron Corporation Apparatus for use with insufflators
US4396152A (en) * 1977-03-02 1983-08-02 Abplanalp Robert H Aerosol dispenser system
US4249526A (en) * 1978-05-03 1981-02-10 Fisons Limited Inhalation device
US4253468A (en) * 1978-08-14 1981-03-03 Steven Lehmbeck Nebulizer attachment
US4338931A (en) * 1979-04-27 1982-07-13 Claudio Cavazza Device for the quick inhalation of drugs in powder form by humans suffering from asthma
US4446862A (en) * 1979-10-30 1984-05-08 Baum Eric A Breath actuated devices for administering powdered medicaments
US4452239A (en) * 1980-03-25 1984-06-05 Hilal Malem Medical nebulizing apparatus
US4423724A (en) * 1980-06-06 1984-01-03 Fisons Limited Inhalation device for powdered medicaments
US4860740A (en) * 1980-10-30 1989-08-29 Riker Laboratories, Inc. Powder inhalation device
US4484577A (en) * 1981-07-23 1984-11-27 Key Pharmaceuticals, Inc. Drug delivery method and inhalation device therefor
US4470412A (en) * 1982-03-19 1984-09-11 Trutek Research, Inc. Inhalation valve
US4823784B1 (en) * 1982-04-30 1991-11-26 Cadema Medical Products Inc
US4823784A (en) * 1982-04-30 1989-04-25 Cadema Medical Products, Inc. Aerosol inhalation apparatus
US4884114A (en) * 1982-08-18 1989-11-28 Siemens Aktiengesellschaft Disconnectable thyristor
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
US4570630A (en) * 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
US4649911A (en) * 1983-09-08 1987-03-17 Baylor College Of Medicine Small particle aerosol generator for treatment of respiratory disease including the lungs
US4534343A (en) * 1984-01-27 1985-08-13 Trutek Research, Inc. Metered dose inhaler
US4674491A (en) * 1984-08-09 1987-06-23 Inge Brugger Inhaler
US4624251A (en) * 1984-09-13 1986-11-25 Riker Laboratories, Inc. Apparatus for administering a nebulized substance
US4677975A (en) * 1984-10-16 1987-07-07 The University Of Auckland Method of dispensing and/or a dispenser
US4807814A (en) * 1985-01-04 1989-02-28 Saint Gobain Vitrage Pneumatic powder ejector
US4942544A (en) * 1985-02-19 1990-07-17 Kenneth B. McIntosh Medication clock
US4668218A (en) * 1985-04-12 1987-05-26 Aktiebolaget Draco Indicating means for a dosage dispensing device
US4986269A (en) * 1985-05-23 1991-01-22 Etela-Hameen Keuhkovammayhdistys R.Y. Respiration therapy apparatus
US4811731A (en) * 1985-07-30 1989-03-14 Glaxo Group Limited Devices for administering medicaments to patients
US5035237A (en) * 1985-07-30 1991-07-30 Newell Robert E Devices for administering medicaments to patients
US4907583A (en) * 1986-03-07 1990-03-13 Aktiebolaget Draco Device in powder inhalators
US4739754A (en) * 1986-05-06 1988-04-26 Shaner William T Suction resistant inhalator
US4926852A (en) * 1986-06-23 1990-05-22 The Johns Hopkins University Medication delivery system phase one
US4926852B1 (en) * 1986-06-23 1995-05-23 Univ Johns Hopkins Medication delivery system phase one
US4819629A (en) * 1986-10-28 1989-04-11 Siemens Aktiengesellschaft Method and apparatus for delivering aerosol to the airways and/or lungs of a patient
US4796614A (en) * 1987-02-26 1989-01-10 Trutek Research, Inc. Collapsible inhalation valve
US5112598A (en) * 1988-05-04 1992-05-12 Hermes Fabrik Pharmazeutischer Preparate Franz Gradinger Gmbh & Co. Kg Vitamin a aerosol-inhalate preparations
US4852561A (en) * 1988-07-27 1989-08-01 Sperry C R Inhalation device
US5027806A (en) * 1988-10-04 1991-07-02 The Johns Hopkins University Medication delivery system phase two
US4984158A (en) * 1988-10-14 1991-01-08 Hillsman Dean Metered dose inhaler biofeedback training and evaluation system
US4995385A (en) * 1989-02-23 1991-02-26 Phidea S.P.A. Inhaler with regular complete emptying of the capsule
US5331953A (en) * 1989-03-07 1994-07-26 Aktiebolaget Draco Device in connection with an inhaler
US5048514A (en) * 1989-07-07 1991-09-17 Somova S.P.A. Inhaler for medicaments contained in capsules
US5033463A (en) * 1989-10-27 1991-07-23 Miat S.P.A. Multi-dose inhaler for medicaments in powder form
US5201308A (en) * 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
US5113855A (en) * 1990-02-14 1992-05-19 Newhouse Michael T Powder inhaler
US5320714A (en) * 1990-02-16 1994-06-14 Byk Gulden Lomberg Chemische Fabrik Gmbh Powder inhalator
US5020527A (en) * 1990-02-20 1991-06-04 Texax-Glynn Corporation Inhaler device with counter/timer means
US5522383A (en) * 1990-06-14 1996-06-04 Rhone-Poulenc Rorer Ltd. Powder inhaler having capsule holding structure and anti-static walls
US5207217A (en) * 1990-07-16 1993-05-04 Promo Pack Sa Multiple single-dose inhaler for medicaments in powder form
US5755221A (en) * 1990-09-12 1998-05-26 Bisgaard; Hans Aerosol inhaler with piston dump
US5099833A (en) * 1991-02-19 1992-03-31 Baxter International Inc. High efficiency nebulizer having a flexible reservoir
US5404871A (en) * 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
US5186164A (en) * 1991-03-15 1993-02-16 Puthalath Raghuprasad Mist inhaler
US5309900A (en) * 1991-03-21 1994-05-10 Paul Ritzau Pari-Werk Gmbh Atomizer particularly for use in devices for inhalation therapy
US5295479A (en) * 1991-04-15 1994-03-22 Leiras Oy Device intended for measuring a dose of powdered medicament for inhalation
US5250287A (en) * 1991-06-14 1993-10-05 Miat S.P.A. Multi-dose insufflator for medicaments in powder form
US5775320A (en) * 1991-07-02 1998-07-07 Inhale Therapeutic Systems Method and device for delivering aerosolized medicaments
US6138668A (en) * 1991-07-02 2000-10-31 Inhale Therpeutic Systems Method and device for delivering aerosolized medicaments
US5458135A (en) * 1991-07-02 1995-10-17 Inhale Therapeutic Systems Method and device for delivering aerosolized medicaments
US6681767B1 (en) * 1991-07-02 2004-01-27 Nektar Therapeutics Method and device for delivering aerosolized medicaments
US5337740A (en) * 1991-08-01 1994-08-16 New England Pharmaceuticals, Inc. Inhalation devices
US5161524A (en) * 1991-08-02 1992-11-10 Glaxo Inc. Dosage inhalator with air flow velocity regulating means
US6119688A (en) * 1991-08-26 2000-09-19 3M Innovative Properties Company Powder dispenser
US6029661A (en) * 1991-08-26 2000-02-29 3M Innovative Properties Company Powder dispenser
US5366122A (en) * 1991-08-27 1994-11-22 Ing. Erich Pfeiffer Gmbh & Co. Kg Dispenser for flowable media
US5363842A (en) * 1991-12-20 1994-11-15 Circadian, Inc. Intelligent inhaler providing feedback to both patient and medical professional
US5645050A (en) * 1991-12-20 1997-07-08 Boehringer Ingelheim Kg Powder inhaler with powder carrier consisting of regular microstructures
US5355872A (en) * 1992-03-04 1994-10-18 Riggs John H Low flow rate nebulizer apparatus and method of nebulization
US5186166A (en) * 1992-03-04 1993-02-16 Riggs John H Powder nebulizer apparatus and method of nebulization
US5355872B1 (en) * 1992-03-04 1998-10-20 John H Riggs Low flow rate nebulizer apparatus and method of nebulization
US5284133A (en) * 1992-07-23 1994-02-08 Armstrong Pharmaceuticals, Inc. Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means
US5349947A (en) * 1993-07-15 1994-09-27 Newhouse Michael T Dry powder inhaler and process that explosively discharges a dose of powder and gas from a soft plastic pillow
US5740794A (en) * 1994-09-21 1998-04-21 Inhale Therapeutic Systems Apparatus and methods for dispersing dry powder medicaments
US5785049A (en) * 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5983893A (en) * 1994-12-21 1999-11-16 Astra Aktiebolag Inhalation device
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US6116237A (en) * 1996-04-29 2000-09-12 Dura Pharmaceuticals, Inc. Methods of dry powder inhalation

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060249144A1 (en) * 2005-05-05 2006-11-09 Pulmatrix Inc. Ultrasonic Aerosol Generator
US20080066741A1 (en) * 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
US20120172788A1 (en) * 2008-04-09 2012-07-05 Bio Bath Corporation Mobile apparatus for the dispersion and transdermal delivery of pharmaceutical, medical or purified carbon dioxide gas
US9713570B2 (en) * 2008-04-09 2017-07-25 Respiderm Corporation Mobile apparatus for the dispersion and transdermal delivery of pharmaceutical, medical or purified carbon dioxide gas
US9642798B2 (en) 2010-09-29 2017-05-09 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
WO2013076654A1 (en) * 2011-11-21 2013-05-30 Levin, Orna Breathing biofeedback device
EP2900133A4 (en) * 2012-09-25 2016-05-25 Inhalation Sciences Sweden Ab Exposure system for aerosol and model material interaction
US9737518B2 (en) 2013-04-01 2017-08-22 Pulmatrix Operating Company, Inc. Tiotropium dry powders
JP2014236973A (en) * 2013-06-06 2014-12-18 ヘレウス メディカル ゲーエムベーハー Medical spraying device with pressure relief valve, and method for producing spray cone
WO2015012758A1 (en) * 2013-07-22 2015-01-29 Inhalation Sciences Sweden Ab Apparatus and method for generating an aerosol

Also Published As

Publication number Publication date
AT189124T (en) 2000-02-15
ES2284226T3 (en) 2007-11-01
CA2112674C (en) 2005-10-04
EP0592540B1 (en) 2000-01-26
EP0940154A3 (en) 1999-09-22
CA2112674A1 (en) 1993-01-21
JPH07501231A (en) 1995-02-09
DE69230613T2 (en) 2000-12-28
ES2141108T3 (en) 2000-03-16
GR3032973T3 (en) 2000-07-31
AT359842T (en) 2007-05-15
DE69233690T2 (en) 2008-01-24
EP0940154A2 (en) 1999-09-08
US5458135A (en) 1995-10-17
EP1693080A2 (en) 2006-08-23
AU2309192A (en) 1993-02-11
DE69233690D1 (en) 2007-05-31
AU662919B2 (en) 1995-09-21
WO1993000951A1 (en) 1993-01-21
EP1693080A3 (en) 2007-07-25
US6138668A (en) 2000-10-31
EP0940154B1 (en) 2007-04-18
JP3230056B2 (en) 2001-11-19
DK0592540T3 (en) 2000-06-26
KR100246082B1 (en) 2000-04-01
DK592540T3 (en)
US5775320A (en) 1998-07-07
CA2444415A1 (en) 1993-01-21
EP0592540A4 (en) 1994-12-07
EP0592540A1 (en) 1994-04-20
DE69230613D1 (en) 2000-03-02

Similar Documents

Publication Publication Date Title
EP1417982B1 (en) Nebulizer apparatus
US5522385A (en) Dynamic particle size control for aerosolized drug delivery
EP0166294B1 (en) Medicament inhalation device
ES2348495T3 (en) Apparatus for delivering an aerosolized medication.
US7331339B2 (en) Methods and systems for operating an aerosol generator
AU723637B2 (en) Dispensing system
US5201308A (en) Powder inhaler
EP1011767B1 (en) Device for administering insulin in controlled dosages by controlling total inhaled volume
EP1670532B1 (en) Unit dose cartridge and dry powder inhaler
JP3282631B2 (en) Pulmonary drug delivery in a range of therapeutically relevant inspiratory flow rate / amount value
CA2320227C (en) Metered dose inhaler agitator
AU681282B2 (en) Dry powder inhaler
US5427089A (en) Valved auxiliary device for use with aerosol container
AU2002255808B2 (en) Inhalation device and method
US6705316B2 (en) Pulmonary dosing system and method
US5960792A (en) Device for aerosolized delivery of peptide drugs
CA1077799A (en) Attachment to medicinal inhalation devices
US8196573B2 (en) Methods and systems for operating an aerosol generator
KR880001811B1 (en) Inhalator(ii)
US5738087A (en) Aerosol medication delivery system
AU749292B2 (en) Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament
US3948264A (en) Inhalation device
AU760749B2 (en) Powder inhaler for combined medicament
Dalby et al. A review of the development of Respimat® Soft Mist™ Inhaler
US6575160B1 (en) Inhalation device

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOVARTIS PHARMA AG, SWITZERLAND

Free format text: ASSIGNMENT OF PATENT RIGHTS;ASSIGNOR:NEKTAR THERAPEUTICS;REEL/FRAME:022071/0001

Effective date: 20081231

Owner name: NOVARTIS PHARMA AG,SWITZERLAND

Free format text: ASSIGNMENT OF PATENT RIGHTS;ASSIGNOR:NEKTAR THERAPEUTICS;REEL/FRAME:022071/0001

Effective date: 20081231